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Preface 
 
 
The objective of the international drug control conventions is to ensure adequate availability of 
narcotic drugs and psychotropic substances for medical and scientific purposes while ensuring that 
such drugs are not diverted for illicit purposes. The International Narcotics Control Board is 
mandated to monitor the implementation of this treaty objective, and has repeatedly voiced its 
concern about the disparate and inadequate access to controlled substances for medical and scientific 
purposes worldwide. 
 
For many years, global consumption of narcotic drugs and psychotropic substances has been  
below the levels required for the most basic treatments. As a result of growing recognition of the 
therapeutic value of controlled substances, as well as the efforts of the international community, 
substantial increases in consumption have been achieved. However, while consumption levels have 
risen in several regions of the world, the bulk of the increase has occurred in a limited number  
of countries, particularly in three regions: Europe, North America and Oceania. Within some 
countries or regions, consumption levels have stagnated or even decreased. As long as these drugs 
remain inaccessible to the large majority of people around the world, patients will not be able  
to derive the health benefits to which they are entitled under the Universal Declaration of  
Human Rights.  
 
For these reasons, the Board has decided to highlight this critical issue in a stand-alone supplement to 
its report for 2010. The supplement presents a thorough analysis of the global situation and regional 
variations in the consumption of internationally controlled substances, identifies the main 
impediments to adequate availability and provides recommendations on how the problem can be 
addressed.  
 
Most narcotic drugs and psychotropic substances controlled under the international drug control 
treaties are indispensable in medical practice. Opioid analgesics, such as codeine and morphine, as 
well as semi-synthetic and synthetic opioids, are essential medicines for the treatment of pain. 
Psychotropic substances such as benzodiazepine-type anxiolytics and sedative-hypnotics and 
barbiturates are indispensable medications for the treatment of neurological and mental disorders. 
Pharmaceutical preparations containing internationally controlled substances play an essential role in 
medical treatment to relieve pain and suffering.  
 
The international drug control treaties continue to be highly effective in preventing the diversion  
of drugs from licit to illicit markets and in protecting society from the consequences of  
dependence. However, in many countries equal attention has not been given to the other objective  
of the treaties — ensuring the adequate availability of controlled substances. Measures taken  
by Governments to prevent the abuse of and trafficking in narcotics drugs and psychotropic 
substances must not hinder the utilization of such drugs for medical treatment. Governments  
need to meet the dual objective of the international drug control treaties, namely, preventing  
the diversion and abuse of internationally controlled substances while ensuring their  
availability for legitimate use. This balance should be reflected in national drug control laws and 
regulations.  
 iv 
The first step towards improving access to these essential drugs for medical and scientific purposes is 
to identify the impediments, which are manifold. While economic considerations may play a role 
with regard to high-cost medications, low cost preparations do exist, and examples of countries 
making use of such preparations demonstrate that economic impediments can be overcome. Systemic 
and regulatory problems may lead to inadequate availability of controlled substances.  
 
To assist Governments in eliminating these impediments, the present supplement includes a wide 
range of practical recommendations that can be tailored to each national situation. I truly hope that 
Governments will make full use of this report to assess the situation in their countries and to 
implement the relevant recommendations. Unless remedial measures are urgently implemented, the 
gap between high-consumption and low-consumption countries may widen, with unnecessary pain 
and suffering continuing in many countries.  
 
 
 
 
 
Hamid Ghodse 
President 
International Narcotics Control Board 
 v 
Summary  
 
The International Narcotics Control Board was invited by the Commission on Narcotic Drugs at its 
fifty-third session, in March 2010, to include in its report for 2010 information on the availability of 
internationally controlled substances for medical requirements. The Board is aware of the growing 
interest of the World Health Organization, other intergovernmental bodies and non-governmental 
organizations in this matter. In recognition of its importance, the Board has decided to devote a 
supplement to its annual report to this subject. This format allows the Board to provide adequate 
information on the present situation, globally and regionally, to highlight major impediments and to 
formulate recommendations to improve the availability of internationally controlled substances for 
medical and scientific purposes. A detailed analysis is contained in the Board’s technical publications 
on narcotic drugs and psychotropic substances. 
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1. Ensuring the availability of internationally controlled substances for treatment in accordance 
with article 9 of the Single Convention on Narcotics Drugs of 1961 (1961 Convention),1 as amended 
by the 1972 Protocol,2 and the preamble of the 1971 Convention on Psychotropic Substances  
(1971 Convention)3 is a mandate of the International Narcotics Control Board.  
 
2. By becoming parties to the international drug control conventions, Governments have accepted 
the obligation to introduce the provisions of those treaties into their national legislation and to 
implement them. The International Narcotics Control Board is the body established by the  
1961 Convention that is responsible for monitoring the compliance of Governments with the 
international drug control treaties and for providing support to Governments in this respect.  
 
3. The conventions established a control regime to serve a dual purpose: to ensure the availability 
of controlled substances for medical and scientific ends while preventing the illicit production of, 
trafficking in and abuse of such substances. The 1961 Convention, while recognizing that addiction to 
narcotic drugs constitutes a serious evil for the individual and is fraught with social and economic 
danger to humankind, affirms that the medical use of narcotic drugs continues to be indispensable 
for the relief of pain and suffering and that adequate provision must be made to ensure the 
availability of narcotic drugs for such purposes. Equally, the 1971 Convention recognizes that, while 
the parties to the Convention were determined to prevent and combat abuse of and trafficking in 
psychotropic substances, their use for medical and scientific purposes is indispensable and that their 
availability for such purposes should not be unduly restricted. The implementation of the 
international drug control treaties by parties is monitored by the Board, whose responsibilities under 
article 9 of the 1961 Convention expressly include the responsibility to ensure the availability of 
narcotic drugs for medical and scientific purposes.  
 
4. The international drug control treaties recognize that narcotic drugs and psychotropic 
substances are indispensable for medical and scientific purposes. However, despite numerous efforts 
by the Board and the World Health Organization (WHO), as well as non-governmental 
organizations, their availability in much of the world remains very limited, depriving many patients 
of essential medicines. The Board continues to monitor the worldwide availability of narcotic drugs 
and psychotropic substances and has made their availability one of the main topics of its dialogue 
with Governments on adequate treaty implementation.  
__________________ 
1  United Nations, Treaty Series, vol. 520, No. 7515. 
2  Ibid., vol. 976, No. 14152. 
3  Ibid., vol. 1019, No. 14956. 
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5. Narcotic drugs such as morphine, fentanyl and oxycodone are opioid analgesics effective for the 
treatment of moderate and severe pain. Data from 2009 show that more than 90 per cent of the global 
consumption of these opioid analgesics occurred in Australia, Canada, New Zealand, the United 
States of America and several European countries. This means that their availability was very limited 
in many countries and in entire regions. Although medical science has the capacity to provide relief 
for most forms of moderate to severe pain, over 80 per cent of the world population will have 
insufficient analgesia, or no analgesia at all, if they suffer from such pain.4 
 
Figure 1. Distribution of morphine consumption, 2009 
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6. Similar disparities exist for the consumption levels of psychotropic substances, although their 
identification is more difficult, as the 1971 Convention does not require Governments to provide 
consumption data on such substances to the Board.  
 
7. Taking into account that the global supply of opiate raw materials is sufficient for the 
production of opioid analgesics such as morphine, codeine and other alkaloids, and does not 
__________________ 
4  There are a number of safe and effective methods to treat pain. Opioid analgesics continue to be the mainstay for the relief of 
moderate to severe pain.  
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constitute a barrier to the availability of narcotic drugs, it should be possible to significantly improve 
this situation through appropriate action by Governments. However, many other barriers to adequate 
availability, identified and highlighted by the Board in the past, continue to exist. The present 
supplement to the report of the Board for 2010 focuses on efforts undertaken to ensure adequate 
availability, developments over recent years and the current levels of availability of narcotic drugs and 
psychotropic substances, and provides recommendations for action to be taken at the international 
and national levels. 
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8. The Board, acting under the mandate assigned to it by the Conventions, was among the first to 
issue a warning that availability of narcotic drugs was not ensured in a majority of countries. More 
than 20 years ago the Board became aware of this problem, being in a singular position to assess 
consumption in various countries. The 1961 Convention requires Governments to submit to the 
Board annual statistical data, including data on the consumption of narcotic drugs. Consumption 
data submitted by Governments are analysed by the Board and then published in its annual technical 
publication on narcotic drugs. While reporting on consumption of psychotropic substances is not 
required by the 1971 Convention, consumption is calculated on the basis of other statistical data 
provided to the Board5 and is published in the annual technical publication on psychotropic 
substances.  
 
9. The regular analysis of consumption data, particularly regarding narcotic drugs, convinced the 
Board that the level of consumption of narcotic drugs was very low in a number of countries. 
Therefore, in 1989, the Board, in cooperation with WHO, assessed the medical need for opiates in the 
world. They found that medical needs for opiates were not being fully satisfied, in particular for the 
treatment of cancer pain.  
 
10. The Board found that only a few countries had established effective systems for assessing 
medical needs. A number of interrelated factors were identified as important impediments. Laws and 
regulations, and their administration or interpretation, unduly impeded the availability of opiates. 
Lack of resources in the health-care system prevented the optimal availability and use of opiates. Fear 
of addiction among professionals and the public was also a deterrent to the appropriate medical 
prescription of opiates. In addition, lack of up-to-date professional training impeded the adequate use 
of opioids to treat pain.  
 
11. The findings of this study were published in the Board’s special report for 1989 on the demand 
for and supply of opiates for medical and scientific needs.6 The Board made a number of 
recommendations to Governments to help them to minimize or overcome many of the impediments 
to making opiates available for medical needs. Governments were requested to examine their 
methods of assessing medical needs for opiates; evaluate their health-care systems and laws and 
regulations for impediments to opiate availability; develop plans of action to facilitate the availability 
of opiates for all appropriate conditions; and establish national policies, guidelines and professional 
education on the rational medical use of opiates. 
__________________ 
5  Data on manufacture, imports, exports and stocks of psychotropic substances. 
6  United Nations publication, Sales No. E.89.XI.5. 
II Action taken by the Board to ensure adequate availability 
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12. Five years later, in 1994, the Board examined the effectiveness of the international drug control 
treaties in a supplement to its annual report, entitled Effectiveness of the International Drug Control 
Treaties.7 In its evaluation the Board concluded that the treaty objective of ensuring an adequate 
supply of narcotic drugs, especially opiates used for medical purposes, had not been universally 
achieved.  
 
13. Therefore, in 1995, the Board published another special report, entitled Availability of Opiates 
for Medical Needs,8 which included specific recommendations to Governments, the United Nations 
International Drug Control Programme, the Commission on Narcotic Drugs, WHO, international 
and regional drug control, health and humanitarian organizations and educational institutions and 
non-governmental health-care organizations, including the International Association for the Study of 
Pain, and other health-care representatives. The recommendations of the special report are still valid. 
Furthermore, chapter I of the report of the Board for 19999 was dedicated to the issue of availability of 
narcotic analgesics. The Board identified in that chapter, inter alia, constraints and impediments to 
the adequate availability of opioids for the treatment of pain and made recommendations to 
Governments for corrective action. As internationally controlled drugs were overused in some 
countries, leading to prescription drug abuse and related problems, chapter I of the report of the 
Board for 200010 dealt with overconsumption of internationally controlled drugs and recommended a 
balanced approach in their use. 
 
14. One tool to assess whether countries improve availability levels, or at least are aware of the 
problem and show the intention to improve, is the analysis of the estimates for narcotic drugs, which 
all countries submit to the Board. The Board regularly contacts countries with missing or particularly 
low estimates in order to ensure adequate availability of opioids for the treatment of pain. This 
practice was formalized in November 1999, when the Board started selecting certain groups of 
countries with low levels of consumption of opioid analgesics (mainly morphine) and with common 
characteristics.11 In 2004 the Board contacted four countries12 that had significantly increased their 
consumption levels and requested information on the policies and activities they considered the main 
causes for their growing consumption of opioid analgesics, in particular morphine, in order to make 
this information available to countries that needed to improve their consumption levels.  
 
15. The matter was repeatedly brought to the attention of Governments in circular letters to all 
countries and specific letters to individual countries. In August 2001, a joint letter from the President 
of the Board and the Chair of the United Nations Development Group was sent to all resident 
coordinators of the United Nations system at the country level, urging them, inter alia, to be aware of 
underconsumption and the lack of medicaments available for the treatment of severe pain in many 
developing countries (see annex II). This request was confirmed in February 2005, in a follow-up 
joint letter from the President of the Board and the Chair of the United Nations Development Group 
(see annex III). In April 2006, the President of the Board emphasized in a letter to all  
__________________ 
7  United Nations publication, Sales No. E.95.XI.5. 
8  United Nations publication, Sales No. E.96.XI.6. 
9  United Nations publication, Sales No. E.00.XI.1.
10 United Nations publication, Sales No. E.01.XI.1. 
11 Main characteristics for selection: no estimates for morphine; large population and very low level of consumption of morphine; 
very high cancer rate and low level of consumption of analgesics; functioning control administration but low level of availability; 
high-income countries outside Europe and North America with inadequate availability. 
12 Brazil, Canada, France, United States of America. 
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countries the difficulties of access to narcotic drugs and psychotropic substances for needy  
patients and encouraged Governments to take measures to ensure the inclusion of  
the subject of rational use of drugs in the curricula of the appropriate university faculties  
(see annex IV).13  
 
16. The subject of availability of opioids for the treatment of pain is discussed with individual 
Governments during all missions of the Board. The letters of recommendation sent to Governments 
after the missions include, if appropriate, specific recommendations on the availability of opioids for 
the treatment of pain. Equally, the WHO guidelines on achieving balance in national opioids control 
policy14 are always included in the information material provided to competent authorities during 
Board missions.  
 
17. The Board regularly includes the subject of the availability of narcotic drugs in speeches at 
meetings of intergovernmental bodies, such as the twentieth special session of the General Assembly, 
sessions of the Commission on Narcotic Drugs, the Economic and Social Council and World Health 
Assembly, and regional meetings of international organizations. In March 2010, at the fifty-third 
session of the Commission on Narcotic Drugs, the discussion of availability resulted in Commission 
resolution 53/4, entitled “Promoting adequate availability of internationally controlled licit drugs for 
medical and scientific purposes while preventing their diversion and abuse”. 
 
18. WHO is the main partner of the Board in activities to increase the availability of opioids for the 
treatment of pain. Specific cooperative activities between the Board and WHO include the promotion 
by the Board of the WHO guidelines on achieving balance in national opioids control policy; the 
establishment of a working group on availability in 2003, which prepared a proposal for 
strengthening working relationships between the Board and WHO with regard to the availability of 
narcotic medicines and promoting rational use of psychotropic medicines; and cooperating in the 
WHO global strategy against pain, aimed at providing assistance to countries in, inter alia, building 
capacity and raising awareness in the area of using opioids in pain treatment.  
 
19. The World Health Assembly, in its resolution WHA58.22, and the Economic and Social 
Council, in its resolution 2005/25, invited WHO and the Board to examine the feasibility of an 
assistance mechanism to facilitate the adequate treatment of pain using opioid analgesics.  
WHO and the Board reviewed documents and studies on the availability of opioid analgesics at the 
country level and examined activities conducted and planned by various bodies to assist 
Governments to ensure the availability of those medicines for legitimate medical use. They concluded 
that although there was no shortage of licitly produced opioid analgesic raw material worldwide and 
global licit consumption of opioids had increased substantially in the past two decades, access to 
opioid analgesics continued to be difficult in many countries, owing to several constraints.  
 
20. WHO and the Board found that an assistance mechanism to facilitate adequate treatment of 
pain using opioid analgesics was feasible. Therefore, WHO started the preparation of the Access to 
Controlled Medications Programme and developed the framework of that Programme in 
consultation with the Board. The Programme is implemented by WHO. The Board actively promotes 
__________________ 
13 Those three letters are also posted on the Board’s website at www.incb.org/incb/en/other-issues_correspondence.html. 
14 World Health Organization, document WHO/EDM/QSM/2000.4. 
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the Programme during its missions, in speeches on the subject of availability and through specific 
references and recommendations in its annual reports.  
 
21. However, while consumption of narcotic drugs for medical purposes had increased significantly 
in some countries, owing inter alia, to the efforts of the Board, the level of availability of substances 
controlled under international conventions remained low and inadequate in most countries. The 
Board therefore concluded that the promotion of a better understanding of the provisions of the 
international drug control treaties was required. One major part of this effort is the provision of 
assistance to Governments in establishing more realistic estimates of requirements for medications 
containing controlled substances. The Board and WHO are at present jointly developing guidelines 
on estimating requirements for substances under international control. This initiative is intended to 
identify methods to be applied by countries to arrive at adequate estimates for narcotic drugs, 
assessments for psychotropic substances and estimates for some precursors for medical purposes. 
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22. “Opiate” is the term generally used to designate drugs derived from opium and their chemically 
related derivatives, such as the semi-synthetic alkaloids, while “opioid” is a more general term for 
both natural and synthetic drugs with morphine-like properties, although the chemical structure may 
differ from that of morphine.  
 
23. The natural alkaloids contained in opium or poppy straw that are under international control 
are morphine, codeine, thebaine and oripavine. Morphine and codeine are under international 
control because of their potential for abuse, while thebaine and oripavine are under such control 
because of their convertibility into opioids subject to abuse. Morphine is the prototype of natural 
opiates and many opioids, and, because of its strong analgesic potency, it is used as a reference 
parameter for comparative purposes. 
 
24. Opioids are used mostly for their analgesic properties to treat severe pain (fentanyl, 
hydromorphone, methadone, morphine and pethidine), moderate to severe pain (buprenorphine15 
and oxycodone) and mild to moderate pain (codeine, dihydrocodeine and dextropropoxyphene). 
They are also used to induce or supplement anaesthesia (fentanyl and fentanyl analogues such as 
alfentanil and remifentanil), as cough suppressants (codeine, dihydrocodeine and, to a lesser extent, 
pholcodine and ethylmorphine) and to treat addiction to opioids (buprenorphine and methadone). 
 
Main opioids controlled under the 1961 Convention and buprenorphinea 
 
Natural alkaloids Semi-synthetic opioids Synthetic opioids 
Morphine Dihydrocodeine Dextropropoxyphene 
Codeine Ethylmorphine Diphenoxylate 
Thebaine Heroin Fentanyl and analogues 
Oripavine Hydrocodone Ketobemidone 
 Hydromorphone Methadone 
 Oxycodone Pethidine 
 Pholcodine Tilidine 
 Buprenorphine  
 
a Buprenorphine is controlled under the 1971 Convention. 
 
25. Semi-synthetic opioids are made by relatively simple chemical modifications of natural  
opiates, such as morphine, codeine and thebaine. Some examples of those derivatives  
are dihydrocodeine, ethylmorphine, heroin, oxycodone and pholcodine. Synthetic opioids are fully 
__________________ 
15 Buprenorphine is controlled under the 1971 Convention. 
III Supply of opiate raw materials and opioids 
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man-made and not related to opiates, although they have similar effects when used in treatment. The 
most commonly used synthetic opioids include fentanyl and fentanyl analogues, methadone and 
pethidine.  
 
 
A. Supply of opiate raw materials 
 
26. Opiates consumed by patients for medical treatment are obtained from opiate raw materials 
(opium, poppy straw and concentrate of poppy straw). Adequate availability of opiate raw materials 
for the manufacture of opiates is therefore a precondition for ensuring the adequate availability of 
opiates used for medical and scientific purposes. 
 
27. Pursuant to the 1961 Convention and the relevant resolutions of the Commission on Narcotic 
Drugs and the Economic and Social Council, the Board examines on a regular basis developments 
affecting the supply of and demand for opiate raw materials. The Board endeavours, in cooperation 
with Governments, to maintain a lasting balance between supply and demand. When analysing the 
situation regarding the supply of and demand for opiate raw materials, the Board uses information 
from Governments of countries producing opiate raw materials, as well as from Governments of 
countries where those materials are utilized for the manufacture of opiates or substances not 
controlled under the 1961 Convention. A detailed analysis of the present situation with regard to the 
supply of opiate raw materials and demand for those materials worldwide is contained in the 2010 
report of the Board on narcotic drugs.16  
 
28. Global stocks of opiate raw materials should cover global demand for about one year to  
ensure the availability of opiates used for medical and scientific purposes in the event of an 
unexpected decline in production resulting from, for example, adverse weather conditions in 
producing countries.17 At the end of 2009, global stocks of opiate raw materials rich in morphine  
were sufficient to cover global demand for 12 months. Global stocks of opiate raw materials rich  
in thebaine were sufficient to cover global demand for slightly less than 12 months; however, that  
was compensated for by the high level of stocks of thebaine and opiates derived from thebaine,  
which were sufficient at the end of 2009 to cover global demand for those opiates for about  
14 months.  
 
29. According to information available to the Board, in 2010 global production of opiate raw 
materials rich in morphine was greater than the utilization of those materials. The global supply 
(stocks and production) of opiate raw materials rich in morphine was fully sufficient to cover global 
demand. For 2011, Governments of producing countries are planning to further extend the area 
cultivated with opium poppy rich in morphine.  
 
30. As for opiate raw materials rich in thebaine, information available to the Board indicates that 
global production exceeded global demand in 2010. Total stocks of opiate raw materials rich in 
thebaine were sufficient to cover global demand for less than one year. The plans of the producing 
countries indicate that global production of opiate raw materials rich in thebaine will exceed global 
__________________ 
16 Narcotic Drugs: Estimated World Requirements for 2011 — Statistics for 2009 (United Nations publication, Sales No. T.11.XI.2). 
17 Report of the International Narcotics Control Board for 2005 (United Nations publication, Sales No. E.06.XI.2), para. 85. 
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demand in 2011 as well. Total stocks of opiate raw materials rich in thebaine are therefore expected to 
increase to a level that can cover about 14 months of demand. The global supply (stocks and 
production) of opiate raw materials rich in thebaine will continue to be sufficient to fully cover global 
demand.  
 
31. Global demand for opiate raw materials rich in morphine and rich in thebaine is expected to 
rise in the future as well. It is anticipated that, as a result of the activities of the Board and WHO to 
ensure the adequate availability of opioid analgesics, global demand for opiates and opiate raw 
materials will continue to rise. 
 
 
 
B. Supply of opioids controlled under the 1961 Convention 
 
32. As in the case of steadily rising production of opiate raw materials, manufacture of opioids has 
also progressively increased in the last 20 years. The manufacture of morphine and the major 
synthetic and semi-synthetic opioids has increased fivefold in the last 20 years, with the synthetic and 
semi-synthetic opioids recording higher growth rates than morphine. This development is strongly 
related to the increasing demand for certain narcotic drugs, as well as the development of new 
products. 
 
 
Figure 2. Growth in manufacture of opioids, 1989-2009 
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33. Figure 2 shows the aggregated growth in manufacture of morphine and synthetic and semi-
synthetic opioids over a period of 20 years. The term S-DDD (defined daily doses for statistical 
purposes) represents a technical unit of measurement used for statistical analysis and is not a 
recommended prescription dose. This unit of measurement is used whenever narcotic drugs or 
psychotropic substances with different levels of potency, and therefore different levels of daily dosage 
in treatment, are aggregated to show the quantities available for a group of substances in a 
comparable unit of measurement. 
 
34. Particularly strong growth rates were recorded for fentanyl, which has become the most 
manufactured synthetic opioid when amounts are expressed in S-DDD. When used as an analgesic, 
fentanyl is about 100 times as potent as morphine and is used for anaesthesia in very small doses (for 
example, 0.005-0.1 mg in injectable form). The use of controlled-release patches of fentanyl for the 
treatment of severe pain, containing higher dosages and used for up to three days, has been increasing 
in all parts of the world resulting in increased manufacture of fentanyl. Methadone is also 
manufactured in much larger quantities than it was 20 years ago, although mostly for use in 
substitution treatment. The manufacture of the semi-synthetic drugs hydrocodone, hydromorphone, 
oxycodone and oxymorphone has also shown very high rates of increase. International trade in 
narcotic drugs increased comparably: fivefold for morphine, by nearly 300 times for fentanyl and by 
more than 130 times for oxycodone.  
 
35. Those are impressive growth rates for manufacture of and international trade in narcotic drugs. 
However, the major reason for those rates was the strong increase in imports in some high-
consumption countries, while most other countries either increased imports to a much lesser extent 
or started out from such low levels that even very high increase rates did not translate into large 
absolute quantities. Moreover, out of 211 countries and territories, 17 did not import any morphine, 
22 did not import any fentanyl and 9 did not import any opioids.  
 
36. Data available to the Board show that the manufacture of morphine and the synthetic and semi-
synthetic opioids at present is fully adequate to satisfy global demand. In addition, ongoing research 
into new applications and preparations allows the manufacture of new medications that are easier 
and more comfortable to use. At the same time, other, less costly types of preparations continue to be 
manufactured. Increasing demand for products in different price ranges can be covered by the 
pharmaceutical industry. The supply side for opioids can therefore not be considered an obstacle to 
the adequate availability of narcotic drugs. 
 
 
C. Supply of opioids currently controlled under the  
1971 Convention 
 
37. Global manufacture of buprenorphine has also risen fivefold in the last 20 years and has  
reached a level comparable to that of the major opioids. It increased sharply in the late 1990s, as the 
substance started to be used in higher doses for the treatment of opioid addiction, and another sharp 
rise is evident since 2006. Equally, international trade in the substance increased sharply, and  
80 countries reported imports of buprenorphine in the period from 2007 to 2009. However, the 
number of countries importing buprenorphine is much smaller than the number of countries 
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importing at least one of the main opioids. There is much less manufacture and trade of pentazocine, 
another major synthetic analgesic controlled under the 1971 Convention, which did not show a 
comparable trend. While there are fluctuations in manufacture and trade, no steady increase rate is 
discernible. 
 
 
D. Supply of stimulants controlled under the 1971 Convention 
 
38. Stimulants included in Schedule II are manufactured in about a dozen countries and imported 
by a further 90 countries. Particularly high growth rates in manufacture in the last  
20 years were recorded for methylphenidate (16-fold) and dexamfetamine (2.5-fold), while 
manufacture of amfetamine18 reached a peak in 1998 and has been declining since. International 
trade of stimulants in Schedule II also increased, more so for methylphenidate than for the 
amphetamines. During the last 10 years the manufacture and trade of stimulants in Schedule IV, 
mostly used as anorectics in anti-obesity treatment, remained at roughly the same level. The level of 
manufacture of the whole group, comprising 14 substances and expressed in S DDD, is below the 
level of manufacture of the major opioids. 
 
 
E. Supply of benzodiazepines and barbiturates controlled under 
the 1971 Convention 
 
39. The manufacture and trade of benzodiazepine-type anxiolytics and sedative hypnotics, after 
strong growth rates 20 years ago, have reached a plateau (between 20 billion and 30 billion S-DDD for 
anxiolytics; between 5 billion and 9 billion S-DDD for sedative-hypnotics) at which they fluctuate. 
Manufacture of barbiturates has also remained stable during the last 10 years. The significant regional 
differences in international trade in anxiolytics and sedative-hypnotics remained, and in certain 
regions that had always reported only very low levels of such imports, further reductions were noted 
(mostly African countries, but also in some parts of Asia). The two most traded psychotropic 
substances in terms of the number of countries importing are diazepam, a benzodiazepine-type 
anxiolytic, and phenobarbital, a barbiturate, both of them imported by more than 160 countries. The 
most manufactured psychotropic substance when expressed in S-DDD is the benzodiazepine-type 
anxiolytic alprazolam. 
 
__________________ 
18 Most of the substances in the schedules of the 1971 Convention are listed by their international non-proprietary names (INN). The 
INN system was developed by WHO to facilitate the identification of pharmaceutical substances or active pharmaceutical 
ingredients. (Those names are used in the technical report of the Board on psychotropic substances.) If no INN exists, the 
substances are listed in the schedules under “other non-proprietary or trivial names”. 
 To most native speakers of English, the INN of many of the substances in Schedule II of the 1971 Convention appear to be 
misspellings: amfetamine, dexamfetamine, levamfetamine, metamfetamine, metamfetamine racemate. In the present report, the 
“other non-proprietary or trivial names” of those substances, which are more common, are used: amphetamine, dexamphetamine, 
levamphetamine, methamphetamine, methamphetamine racemate. 
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40. Adequate supply of licitly produced opiate raw materials and of the end products manufactured 
using those raw materials, as well as increasing manufacture of psychotropic substances, does  
not necessarily lead to adequate supply of medicines containing those substances for the end-user,  
the patient. Access to opioid-based medicines, as well as other medicines containing substances  
under international control, is limited or almost non-existent in many countries. That  
discrepancy has been discussed repeatedly not only by the Board but also by the Commission on 
Narcotic Drugs.  
 
41. As mentioned above, the Commission on Narcotic Drugs, in its resolution 53/4, entitled 
“Promoting adequate availability of internationally controlled licit drugs for medical and scientific 
purposes while preventing their diversion and abuse”, recalled the 1961 Convention as amended by 
the 1972 Protocol, as well as the 1971 Convention. That resolution reflects the recognition in both 
Conventions that internationally controlled substances are indispensable for medical treatment and 
scientific purposes. In that resolution the Commission recalled that the availability of internationally 
controlled substances should not be unduly restricted and that provision must be made to ensure 
their availability for medical and scientific purposes.  
 
42. In the same resolution, the Commission invited the Board to include in its annual report for 
2010 information on the consumption of narcotic drugs and psychotropic substances used for 
medical and scientific purposes worldwide, including an analysis of impediments to their adequate 
availability, actions to be taken to overcome those impediments and, when available, specific 
information about the status of and progress made by countries. Pursuant to that resolution, the 
Board carried out an analysis of global developments and regional patterns of consumption of opioid 
analgesics based on statistics furnished by Governments. It also analysed the global developments and 
regional patterns of consumption of psychotropic substances.19  
 
43. In order to show discrepancies between regions, as well as between countries within regions,  
the Board’s technical publication on narcotic drugs provides regional tables on consumption  
levels of opioid analgesics, in addition to the global table on average consumption of narcotic drugs 
(table XIV of the technical publication on narcotic drugs). Governments are required to provide  
to the Board, in their annual statistics on narcotic drugs, data on the consumption of opioid 
analgesics. Countries have been collecting such data for many years, but not all of them have 
developed adequate methods of assessing their requirements. The Board has created the concept of 
“defined daily doses for statistical purposes (S-DDD) consumed per million inhabitants per day”, 
__________________ 
19 Calculated on the basis of statistical data furnished to the Board on manufacture, imports, exports and stocks. 
IV Availability of medicines containing  internationally controlled substances 
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which it uses when compiling and comparing statistics on the consumption of substances with 
different potency levels, such as opioid analgesics.  
 
44. In the absence of a universally agreed expert opinion on adequate levels of consumption, the 
Board has internally, for administrative purposes, set some minimum standards to use when 
examining estimates of annual requirements for narcotic drugs submitted by countries. The Board 
has identified levels of consumption that it considers to be inadequate (consumption of opioid 
analgesics in quantities between 100 and 200 S-DDD per million inhabitants per day) or very 
inadequate (consumption of opioid analgesics in quantities equal to or less than 100 S-DDD). If those 
levels were to be used as a benchmark, 21 countries would have inadequate consumption levels and 
more than 100 other countries would have very inadequate consumption levels, most of them in 
Africa. In May 2004, the Board adopted an amendment to the rules for establishing estimates, which 
allowed for the raising of the estimates of certain essential narcotic drugs by the Board in case the 
existing estimates were considered inappropriately low. 
 
45. In its resolution 53/4 the Commission on Narcotic Drugs invited the Board to present to the 
Commission information on the consumption of psychotropic substances used for medical and 
scientific purposes worldwide, to promote their adequate availability. However, Governments are not 
obliged to submit data on the consumption of psychotropic substances. The Board has found it useful 
in the past to calculate approximate consumption levels for psychotropic substances based on the 
statistical information on those substances that Governments have submitted to the Board in their 
annual statistics on psychotropic substances, to show global trends and, when data appear to be 
consistent and reliable, to identify unusual consumption patterns. As stated in the technical report of 
the Board on psychotropic substances, caution should be exercised when drawing conclusions on the 
actual level of consumption of psychotropic substances, at the global level as well as in specific 
countries, as data reported by Governments on the manufacture of and trade in psychotropic 
substances may not be complete or may not cover all substances. Calculated consumption levels tend 
to be particularly inaccurate for manufacturing countries. The calculated consumption levels are 
published in table IV of the technical report on psychotropic substances. 
 
46. In the past, the analysis of calculated consumption levels of psychotropic substances often 
focused on consistently high levels of consumption that might not be medically justified and might 
lead to the diversion and abuse of the substances in question. However, the Board was aware that the 
very low levels of consumption of psychotropic substances observed in some countries might reflect 
the fact that those substances were almost inaccessible to certain segments of the population and that 
those substances, or counterfeit medicaments allegedly containing those substances, might therefore 
appear on unregulated markets to cover the unmet needs. It should also be taken into consideration 
that consumption levels for psychotropic substances vary greatly between countries and regions, 
because of differences in medical practice and related variations in prescription patterns. 
Comparisons between countries and regions can be made only with great care, especially since, for 
certain psychotropic substances, other psychotropic substances or non-psychotropic substances may 
be used as substitutes, which should be taken into account when reviewing the availability of those 
psychotropic substances.  
 
47. The Board notes that on numerous occasions Governments have strengthened the 
international control regime for psychotropic substances by agreeing to provide additional data to 
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the Board, such as assessments of annual requirements for those substances and details on trade in 
substances in Schedules III and IV of the 1971 Convention and on stocks held by manufacturers. 
Since such data were not considered essential when the 1971 Convention was adopted, it was the 
Economic and Social Council that, in various resolutions,20 introduced the requirement to collect and 
submit to the Board the above-mentioned additional information on psychotropic substances. 
Although this additional reporting is not yet universal, the Board appreciates the fact that most 
Governments submit the additional information pursuant to the resolutions of the Economic and 
Social Council and offers training for the national authorities responsible for completing and 
returning the forms. 
 
48. In the opinion of the Board, it is again time for Governments to agree to voluntarily provide it 
with information not foreseen under the 1971 Convention but essential for the implementation of 
Commission on Narcotic Drugs resolution 53/4 so that the Board will be in a position to analyse 
trends in the consumption of psychotropic substances. Reliable data on the consumption of 
psychotropic substances will also be needed to assess the effectiveness of any measures taken in 
accordance with Commission resolution 53/4. The Board therefore strongly recommends that 
Governments consider providing it with data on the consumption of psychotropic substances, to 
enable the Board to comply with Commission resolution 53/4 and, ultimately, to promote the 
adequate availability of psychotropic substances used for medical and scientific purposes while 
preventing the diversion and abuse of those substances.  
 
49. For the reasons mentioned above, the quality of data on the consumption of psychotropic 
substances is not comparable with the quality of data on the consumption of narcotic drugs. It is 
therefore more difficult to provide a meaningful analysis of the consumption levels for psychotropic 
substances. Moreover, in most countries psychotropic substances are used much more in medical 
treatment than narcotic drugs. To analyse the consumption patterns of psychotropic substances, the 
Board therefore uses the concept of S-DDD consumed per thousand inhabitants per day to compare 
and compile statistics of substances of different potency. Therefore, the information below is divided 
into information on consumption levels of opioid analgesics and information on analgesics 
controlled under the 1971 Convention, as well as information on other groups of psychotropic 
substances.  
 
50. The situation with regard to the adequacy of consumption levels for psychotropic substances is 
similar to the situation with regard to the adequacy of consumption levels for narcotic drugs: there is 
no agreement among experts regarding the level of per capita consumption of any of the groups of 
psychotropic substances that is implied by “adequate availability”.  
 
51. The Commission on Narcotic Drugs, in its resolution 53/4, affirmed that the international drug 
control conventions sought to achieve a balance between ensuring the availability of narcotic drugs 
and psychotropic substances under international control for medical and scientific purposes and 
preventing their diversion and abuse. In the same resolution the Commission acknowledged that an 
increase in the licit supply of internationally controlled substances might increase the risk of 
diversion and abuse of those substances. The present supplement includes information on the 
consumption levels for certain groups of substances that may be considered too high. It is apparent 
__________________ 
20 Resolutions 1981/7, 1985/15, 1987/30 and 1991/44. 
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that in a few countries with high levels of consumption, narcotic analgesics are the main drug abuse 
problem and that the abuse of prescription drugs is increasing. 
 
 
A. Availability of opioid analgesics controlled under the  
1961 Convention 
 
52. In the period 1989-2009, global consumption of opioid analgesics used for the treatment of 
moderate and severe pain increased considerably. For example, global consumption of morphine 
increased sevenfold. The increase was more dramatic for certain opioids under international control, 
such as fentanyl (100-fold) and oxycodone (26-fold). The increase was significantly higher in some 
regions than in others.21 Within each region, the increase in consumption was greater in some 
countries than in others, and there continued to be large differences in the consumption levels of 
different countries. Consumption levels in regions, countries and territories are reflected in the tables 
in annex I. 
 
Figure 3. All regions: average consumption of opioid analgesics, 1987-1989, 1997-1999  
and 2007-2009 
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__________________ 
21 Figures 3-13 provide information on the development in consumption levels of opioid analgesics globally and regionally over the 
last 20 years. Due to the significant differences in consumption levels, the scales used in the graphs are different. 
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53. The highest levels of consumption for opioid analgesics have been recorded in North American 
and European countries and Australia and New Zealand. In a large proportion of countries in  
Europe and North America the levels of consumption for opioid analgesics rose substantially  
in the period 2000-2009. Canada and the United States had the highest levels of consumption  
for opioid analgesics in the world. Those two countries recorded a consistent increase in  
their consumption of opioid analgesics from 1989 to 2009, when the consumption levels  
reached nearly 40,000 S-DDD per million inhabitants per day in the United States and more than 
20,000 S-DDD in Canada, compared with 85 S-DDD per million inhabitants per day in Mexico. 
 
54. In Europe, the consumption levels for opioid analgesics used for the treatment of pain also 
increased dramatically in the period 2000-2009. However, there continue to be large disparities in 
those consumption levels among European countries. The two countries with the highest 
consumption levels, Germany and Austria, reported consumption of about 20,000 and  
16,000 S-DDD per million inhabitants per day, respectively. Five other countries reported 
consumption levels of more than 10,000 S-DDD and 21 countries reported levels between  
1,000 and 10,000 S-DDD. In some countries in the region, mostly in Eastern and South-Eastern 
Europe, consumption levels increased only slightly or even decreased. Consumption in 3 countries 
(Belarus, Romania and the Russian Federation) amounted to fewer than 200 S-DDD per million 
inhabitants per day.22 Four countries reported consumption levels below 100 S-DDD (Albania, 
Republic of Moldova, the former Yugoslav Republic of Macedonia and Ukraine). 
 
 
Figure 4. North America: average consumption of opioid analgesics, 1997-1999  
and 2007-2009 
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22 Narcotic Drugs: Estimated World Requirements for 2011 — Statistics for 2009 (see footnote 16 above), table XIV. 
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Figure 5a. Europe (countries with higher consumption): average consumption of opioid 
analgesics, 1997-1999 and 2007-2009 
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a Data not available, as the territory did not submit statistical forms for the three consecutive years 1997-1999. 
 
Figure 5b. Europe (countries with lower consumption): average consumption of opioid 
analgesics, 1997-1999 and 2007-2009 
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a Data for 1997-1999 not available, as the country was not admitted to membership in the United Nations until 2006. 
b Data not available, as the country did not submit statistical forms for the three consecutive years 1997-1999. 
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55. Significant increases in the consumption of opioid analgesics also occurred in the  
period 2000-2009 in some countries in East and South-East Asia, West Asia, South America and 
Oceania. Despite those increases, the level of consumption of opioid analgesics remained relatively 
low in most countries in those regions. 
 
56. In East and South-East Asia, the consumption levels for opioid analgesics in 65 per cent of the 
countries in the region amounted to fewer than 100 S-DDD per million inhabitants per day in the 
period 2007-2009. The highest levels of consumption were reported in Japan and the Republic of 
Korea, the two countries in the region that recorded the most dramatic increase in such consumption 
during the past decade (more than 1,000 S-DDD per million inhabitants per day). However, in most 
countries in the region, consumption levels for opioid analgesics increased only slightly. More than 
80 per cent of the countries reported consumption levels below 200 S-DDD. In Cambodia, Indonesia, 
the Lao People’s Democratic Republic and Myanmar, those consumption levels were below 10 S-
DDD per million inhabitants per day. No consumption of opioid analgesics was reported by Timor 
Leste. 
 
Figure 6. East and South-East Asia: average consumption of opioid analgesics, 1997-1999  
and 2007-2009 
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57. In West Asia, the consumption levels for opioid analgesics in more than 60 per cent of the 
countries in the region amounted to fewer than 100 S-DDD per million inhabitants per day in the 
period 2007-2009. Consumption levels in Israel have been substantially higher than in the  
other countries in the region and increased steadily over a 20-year period, reaching more than 3,000 
S-DDD per million inhabitants per day in the period 2007-2009. The consumption levels for opioid 
analgesics used for the treatment of pain increased significantly in the period 2000-2009 in Bahrain 
and Turkey. Consumption increased but remained below 200 S-DDD in Jordan, Kuwait, Lebanon, 
200 S-DDD
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Qatar, Saudi Arabia and the United Arab Emirates. In Afghanistan, Iraq, Pakistan, Tajikistan, 
Uzbekistan and Yemen, consumption levels were below 10 S-DDD per million inhabitants per day  
in 2009. 
 
Figure 7. West Asia: average consumption of opioid analgesics, 1997-1999 and 2007-2009 
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* Data not available, as the country did not submit statistical forms for the three consecutive years 1997-1999. 
 
58. In South America, the consumption levels for opioid analgesics in more than  
50 per cent of the countries in the region amounted to fewer than 100 S-DDD per million inhabitants 
per day in the period 2000-2009, although consumption levels in the region  
as a whole increased significantly. In about half of the countries in the region, consumption of opioid 
analgesics more than doubled during that period. The highest consumption  
level in the period 2007-2009 was reported by the Falkland Islands (Malvinas), with  
4,283 S-DDD per million inhabitants per day. Argentina and Chile reported consumption levels of 
about 400 S-DDD per million inhabitants per day. Bolivia (Plurinational State of) and Guyana 
reported consumption of opioid analgesics to be no more than 10 S-DDD per million inhabitants  
per day. 
 
59. In Oceania, the situation with regard to consumption levels in the different countries is sharply 
divided. Of 15 reporting countries, 6 (40 per cent) have consumption levels below  
100 S-DDD per million inhabitants per day. On the other hand, 7 countries (47 per cent) reported 
consumption of more than 1,000 S-DDD. The consumption levels for opioid analgesics in  
Australia for the period 2007-2009 (more than 8,000 S-DDD) were substantially higher than in the 
other countries in the region. Despite significant increases in the consumption levels for opioid 
analgesics in the Marshall Islands, Nauru, Papua New Guinea, Samoa, Tonga and Vanuatu, 
consumption levels remained low (less than 100 S-DDD per million inhabitants per day). 
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Figure 8. South America: average consumption of opioid analgesics, 1997-1999  
and 2007-2009 
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Figure 9. Oceania: average consumption of opioid analgesics, 1997-1999 and 2007-2009 
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60. In contrast to the developments in the above-mentioned regions, consumption levels for opioid 
analgesics in Africa, Central America and the Caribbean and South Asia did not increase significantly 
in the period 2000-2009. Modest increases were recorded in a few countries in each of those  
three regions. As a result, in the vast majority of the countries in those regions consumption of opioid 
analgesics amounted to fewer than 100 S-DDD per million inhabitants per day, and in a large number 
of those countries less than 10 S-DDD or even zero. 
 
61. Africa has continued to be the region with the lowest levels of consumption for opioid 
analgesics. Only one country reported consumption above 200 S-DDD per million inhabitants  
per day, and four others reported consumption of above 100 S-DDD. In nearly 90 per cent of the 
countries in the region, such consumption amounted to fewer than 100 S-DDD per million 
inhabitants per day, and nearly half of the countries in the region had levels below 5 S-DDD. 
Significant increases in consumption have been limited to a few countries, and it has decreased in 
several others. South Africa currently has the highest consumption level for opioid analgesics in the 
region, averaging 600 S-DDD per million inhabitants per day. In six countries in the region 
(Cameroon, Chad, Mali, Nigeria, Rwanda and United Republic of Tanzania), average consumption of 
opioid analgesics amounted to less than 1 S-DDD per million inhabitants per day.  
No consumption of opioid analgesics was reported by the Central African Republic,  
the Congo, Djibouti, Equatorial Guinea, the Gambia, Guinea, Guinea-Bissau, Liberia, Somalia  
or Swaziland. 
 
 
 
Figure 10a. Africa (countries with higher consumption): average consumption of opioid 
analgesics, 1997-1999 and 2007-2009 
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* Data not available, as the country did not submit statistical forms for the three consecutive years 1997-1999. 
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Figure 10b. Africa (countries with lower consumption): average consumption of opioid 
analgesics, 1997-1999 and 2007-2009 
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* Data not available, as the country did not submit statistical forms for the three consecutive years 1997-1999. 
 
62. In Central America and the Caribbean, consumption levels for opioid analgesics remained 
relatively low in the period 1989-2009. More than half of the countries in the region reported  
levels of fewer than 100 S-DDD of opioid analgesics per million inhabitants per day in the  
period 2007-2009. Only the Cayman Islands and the Netherlands Antilles reported consumption 
above 1,000 S-DDD per million inhabitants per day. Haiti reported average consumption of  
2 S-DDD per million inhabitants per day. No consumption of opioid analgesics was reported by 
Anguilla, Antigua and Barbuda, Aruba, Barbados, Belize, the British Virgin Islands, Honduras or 
Saint Kitts and Nevis. 
 
63. All countries in South Asia reported very low consumption levels of opioid analgesics during 
the period 2007-2009. The highest consumption level was reported by Sri Lanka, with 26 S-DDD. 
Bhutan was the only other country with a consumption level above 20 S-DDD. Bangladesh and Nepal 
reported consumption of less than 10 S-DDD. 
 
64. As indicated in the paragraphs above, there continue to be large disparities among countries  
in terms of the consumption of opioids. Opioid analgesics under international control continue  
not to be available in sufficient quantities to meet the medical requirements of the population in 
many countries throughout the world, including in several countries with very large populations, 
such as India and Nigeria. In some other countries, however, overprescribing and the availability  
of opioid analgesics in quantities greater than those required for sound medical treatment  
may lead to the diversion and abuse of those substances, which some countries are already 
experiencing.  
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Figure 11. Central America and the Caribbean: average consumption of opioid analgesics,  
1997-1999 and 2007-2009 
 
 0
 200
 400
 600
 800
1 000
1 200
1 400
S
-D
D
D
 p
e
r 
m
ill
io
n
 i
n
h
a
b
it
a
n
ts
 p
e
r 
d
a
y
1997-1999 2007-2009
2
 9
0
9
C
a
ym
a
n
 I
sl
a
n
d
s
N
e
th
e
rl
a
n
d
s 
A
n
ti
lle
s
T
u
rk
s 
a
n
d
 
C
a
ic
os
 I
sl
a
n
d
s
B
a
h
a
m
a
s
M
o
n
ts
e
rr
a
t*
T
ri
n
id
ad
 a
n
d
 
T
o
b
a
g
o
*
P
a
n
a
m
a
C
os
ta
 R
ic
a
S
a
in
t 
Lu
ci
a
E
l 
S
a
lv
a
d
o
r*
C
u
b
a
Ja
m
a
ic
a
S
a
in
t 
V
in
ce
n
t 
a
n
d
 t
h
e 
G
re
n
a
d
in
es
G
re
n
ad
a
G
u
a
te
m
a
la
D
o
m
in
ic
a
N
ic
a
ra
g
u
a
D
o
m
in
ic
a
n
 
R
e
p
u
b
lic
H
a
it
i*
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Figure 12. South Asia: average consumption of opioid analgesics, 1997-1999  
and 2007-2009 
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B. Opioids controlled under the 1971 Convention 
 
 
 
65. Buprenorphine, lefetamine and pentazocine are the analgesics controlled under the  
1971 Convention. The consumption of buprenorphine, an opioid analgesic in Schedule III of  
the 1971 Convention, accounted for over 99 per cent of global consumption of such analgesics in 
2009. Calculated consumption of buprenorphine increased sharply in the period 1990-2009,  
although the information available is not accurate enough to allow the level of consumption to be 
calculated for each of the major manufacturing and consuming countries. Two decades ago, 
buprenorphine was used in only 12 countries, none of them in Africa or Oceania. In the period 2007-
2009, buprenorphine was used in about 75 countries or territories, representing every region,  
or about 35 per cent of all countries and territories. That shift in the use of buprenorphine  
is attributable to its increasing use in higher-dosage forms for the treatment of pain and for 
substitution treatment. Australia, Belgium, France, Germany, Norway, the United Kingdom of Great 
Britain and Northern Ireland and the United States are the countries with the highest consumption 
levels for buprenorphine. Europe has consistently been the region with the highest levels of 
consumption.  
 
 
66. From the information available, it is not possible to identify countries with  
problematic consumption patterns (consumption levels that are too low or too high), mainly because 
of the reporting problems mentioned above, but also because certain narcotic drugs  
(for example, any opioid analgesic for the treatment of pain and methadone for substitution 
treatment) might be used as a substitute for buprenorphine, and its availability should be  
reviewed in connection with the availability of those drugs. The diversion of buprenorphine from 
domestic distribution channels, above all from substitution treatment programmes, continues  
to occur. 
 
 
67. Pentazocine is an opioid analgesic with properties and uses similar to those of morphine; it is 
listed in Schedule III of the 1971 Convention. In the period 2005-2009, global calculated consumption 
of pentazocine showed a slight increase. In contrast to the use of buprenorphine, pentazocine use is 
not spreading to other countries; the same 50 countries have been using pentazocine during the last 
decade, among which India, Pakistan and the United States together accounted for 80 per cent of the 
global total in the period 2007-2009.  
 
 
 
C. Anti-epileptics 
 
 
 
68. Clonazepam (a benzodiazepine), methylphenobarbital and phenobarbital are the  
anti-epileptics controlled under the 1971 Convention. All three of them are in Schedule IV of  
that Convention. In addition to being used for the treatment of epilepsy, they are used to induce 
sleep. From the data reported to the Board, it is not possible to determine the extent to which the 
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substances are used to induce sleep and the extent to which they are used to treat epilepsy.  
The consumption of phenobarbital accounted for over 99 per cent of global consumption of  
anti-epileptics in 2009.  
 
 
69. Calculated consumption of anti-epileptics increased in the period 1990-2009. In 1990,  
the use of those substances was reported in 120 countries throughout the world. Since then, their  
use has spread to virtually every country, and phenobarbital is one of the most widely used 
psychotropic substances. As is the case for all psychotropic substances, calculated consumption levels 
for anti-epileptics based on the data reported to the Board are very tentative, as some major 
manufacturers and importers submit inaccurate or inconsistent data. The countries with the highest 
consumption levels for anti-epileptics are Bulgaria, Latvia and Ukraine. Europe has consistently been 
the region with the highest consumption levels for those substances.  
 
 
70. In Benin, the consumption levels for anti-epileptics (7 S-DDD per million inhabitants  
per day in 2008) are much higher than the average for Africa, which could indicate  
excessive availability linked to non-implementation of the prescription requirements foreseen  
by the 1971 Convention, as well as the possibility of related diversion and abuse. The information 
available to the Board does not allow conclusions to be drawn as to whether the substances  
are available in all countries in sufficient quantities, in particular as anti-epileptics.  
Diverted phenobarbital is sometimes found on illicit markets, possibly because the substance is not 
available on licit markets in the quantities required. There have been enquiries from hospitals 
indicating that in some countries the quantities of phenobarbital imported for medical purposes are 
not sufficient.  
 
 
 
D. Stimulants in Schedule II of the 1971 Convention that are used 
for the treatment of attention deficit disorder 
 
 
 
71. Methylphenidate, amphetamine and dexamphetamine, substances in Schedule II of the  
1971 Convention, are used mainly for the treatment of attention deficit disorder (ADD)  
and narcolepsy. For many years, the most extensive use of those substances for medical  
purposes has been in the Americas. In recent years, the highest levels of consumption for  
those stimulants have been observed in Canada, Israel, the United States and countries in northern 
Europe.  
 
 
72. Methylphenidate is the most widely used stimulant in Schedule II of the 1971 Convention.  
Its manufacture and use continue to increase. In the period 2005-2009, global calculated 
consumption of methylphenidate increased by 30 per cent, reaching 40 tons, the majority of  
which was accounted for by the United States. In that country, the use of methylphenidate for the 
treatment of ADD continues to be promoted in advertisements directed at potential consumers, 
28 
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contrary to the provisions of the 1971 Convention. The use of methylphenidate for the treatment  
of ADD has been growing in many other countries as well, although the use of the substance 
continues to be much greater in the United States than in all the other countries combined. Countries 
other than the United States together accounted for less than 20 per cent of global calculated 
consumption of methylphenidate in 2000; however, that proportion gradually increased to  
30 per cent by 2009.  
 
 
73. During the period 2007-2009, about 100 countries and territories reported the use of 
methylphenidate and about 70 reported the use of amphetamines. Stimulants in Schedule II of the 
1971 Convention appear not to be available in about 50 per cent of all countries and territories. Since 
2007, Iceland, followed by the United States, has been the country with the highest calculated per 
capita consumption of methylphenidate. Figure 13 shows the countries with consumption rates of 
methylphenidate above 1 S-DDD per thousand inhabitants per day, ranked by their calculated 
consumption levels. 
 
 
 
 
 
Figure 13. Selected countries: average consumptiona of methylphenidate, 1997-1999  
and 2007-2009 
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a Approximate consumption calculated by the Board. 
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74. As previously noted by the Board, the diversion and abuse of stimulants in Schedule II of the 
1971 Convention take place in countries with very high levels of consumption of those substances. 
The Board reiterates its request to all Governments to ensure that the control measures foreseen in 
the 1971 Convention are fully applied to stimulants in Schedule II.  
 
 
 
 
 
E. Stimulants in Schedule IV of the 1971 Convention that are used 
as anorectics 
 
 
 
75. The stimulants in Schedule IV of the 1971 Convention are used mainly as anorectics. The most 
frequently used stimulant in Schedule IV is phentermine, followed by fenproporex, amfepramone 
and mazindol. 
 
 
 
 
Figure 14. All regions: average consumptiona of central nervous system stimulants in Schedule 
IV, 1997-1999 and 2007-2009 
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a Approximate consumption calculated by the Board. 
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Figure 15. Selected countries and territories: average consumptiona of central nervous system 
stimulants in Schedule IV, 1997-1999 and 2007-2009 
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Figure 16. All regions: number of countries and territories using central nervous system 
stimulants in Schedule IV, 2007-2009 
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76. The highest calculated consumption levels for stimulants in Schedule IV of the  
1971 Convention have traditionally been recorded in countries in the Americas, in particular 
Argentina, Brazil and the United States. In the period 2007-2009, average calculated  
consumption in the Americas continued to increase, and the United States remained the country with 
the world’s highest calculated per capita consumption levels for those stimulants.  
Until 2006, Brazil had similar levels of consumption. Between 2006 and 2009, Brazil succeeded in 
reducing per capita consumption of those stimulants by two thirds by strictly enforcing  
the prescription requirement and taking action against members of the medical profession who were 
found to have acted in an unprofessional manner. The share of global calculated consumption of 
stimulants in Schedule IV (expressed in S-DDD) accounted for by the United States increased  
from 58 per cent in 2008 to 71 per cent in 2009. The declining demand for stimulants has been  
noted by the industry: in 2009 global manufacture of this group of stimulants decreased by 25 per 
cent from the level of previous years, mainly because of a drop in the manufacture of fenproporex  
in Brazil. 
 
 
77. About 75 countries and territories report regular use of stimulants included in Schedule IV of 
the 1971 Convention. Figure 15 reflects the fact that consumption levels of those stimulants vary 
greatly between countries and regions, whereas figure 16 shows for each region the number of 
countries and territories that reported such use. In about 60 per cent of all the countries and 
territories, those stimulants appear not to be available; their availability is particularly limited in 
Africa, the island countries of Oceania and much of Asia. 
 
 
78. In a number of countries, high prescription levels for stimulants in Schedule IV have led to the 
diversion and abuse of those stimulants. The Board encourages Governments to remain vigilant and 
identify consumption levels that are inappropriate and/or not required for sound medical  
practice and to take steps to fully apply the control measures foreseen in the  
1971 Convention. 
 
 
 
F. Benzodiazepines 
 
 
79. For benzodiazepines, global calculated consumption shows a slight increase in the last  
decade. During that period, practically all countries and territories that reported to the Board 
manufactured or traded in benzodiazepines in quantities of more than 1 kg at least once. Among 
anxiolytics, alprazolam and diazepam are the most used substances, whereas triazolam was the  
most consumed sedative-hypnotic. Reporting obligations for substances included in Schedules III 
and IV, such as benzodiazepines, are less stringent than for Schedule II substances. Calculated 
consumption levels for these types of substances are therefore more approximate than for Schedule II 
substances.23  
__________________ 
23 Figures 17 to 28 provide information on global and regional developments in consumption levels of benzodiazepines over the last 
10 years. Owing to the significant differences in consumption levels, the scales used in the figures vary. 
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Benzodiazepine-type anxiolytics 
 
 
80. As can be seen in figure 17, consumption levels of benzodiazepine-type anxiolytics are  
highest in countries in Europe, reflecting the fact that benzodiazepines tend to be prescribed 
frequently for the elderly. As reflected in figures 19 to 22, consumption levels of benzodiazepine-type 
anxiolytics in countries outside of Europe in the period 2007-2009 tended to be lower than  
20 S-DDD per thousand inhabitants per day, although there were a few exceptions. 
 
 
 
Figure 17. All regions: average consumptiona of benzodiazepines (anxiolytics), 1997-1999  
and 2007-2009 
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81. Consumption of anxiolytics in many countries in Europe during the last decade increased  
from an already high level. Between 2007 and 2009, in 12 countries (about 27 per cent of the  
region), calculated average consumption levels exceeded 40 S-DDD per thousand inhabitants, and in 
another 14 countries (31 per cent) those levels were between 20 and 40 S-DDD per thousand 
inhabitants. Countries in Western and South-Eastern Europe have the highest consumption levels in 
the region. 
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Figure 18. Europe (selected countries): average consumptiona of benzodiazepines (anxiolytics), 
1997-1999 and 2007-2009  
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a Approximate consumption calculated by the Board. 
b Countries constituted after 1999, therefore, no data are available for the period 1997-1999. 
c Data received do not allow calculation of approximate consumption for the period 1997-1999. 
 
 
 
 
82. In Africa, Ghana showed the highest average calculated consumption of anxiolytics  
(16 S-DDD per thousand inhabitants) in the period 2007-2009. For six countries (Algeria, Benin, 
Cape Verde, Democratic Republic of the Congo, Tunisia and South Africa), consumption was 
between 5 and 10 S-DDD per thousand inhabitants per day. Eight countries, as shown in figure 19, 
had consumption levels between 1 and 5 S-DDD per thousand inhabitants per day, whereas in all 
other countries and territories (73 per cent of the region) less than 1 S-DDD per thousand inhabitants 
per day was consumed. 
 
 
83. In Asia, seven countries (Islamic Republic of Iran, Iraq, Israel, Japan, Jordan, Pakistan and 
Republic of Korea) (15 per cent of the countries and territories) showed an average calculated 
consumption level of anxiolytics higher than 10 S-DDD per thousand inhabitants per day between 
2007 and 2009, whereas in four countries and two territories (Lebanon, Sri Lanka, Syrian Arab 
Republic, Thailand, Hong Kong, China and Macao, China) consumption levels between 5 and  
10 S-DDD per thousand inhabitants per day were observed. Ten countries (Bahrain,  
Cambodia, China, Georgia, India, Kuwait, Republic of Korea, Singapore, Turkey and Yemen) 
consumed between 2 and 5 S-DDD per thousand inhabitants per day. The remaining  
44 per cent of the countries and territories in Asia consumed less than 2 S-DDD per thousand 
inhabitants per day. 
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Figure 19. Africa (selected countries): average consumptiona of benzodiazepines (anxiolytics), 
1997-1999 and 2007-2009 
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a Approximate consumption calculated by the Board. 
 
Figure 20. Asia (selected countries and territories): average consumptiona of benzodiazepines 
(anxiolytics), 1997-1999 and 2007-2009 
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84. In Oceania, two countries and two territories (Australia, New Zealand, French Polynesia and 
New Caledonia) consumed on average more than 5 S-DDD of anxiolytics per thousand inhabitants 
per day in the period 2007-2009. All other countries and territories consumed considerably less. 
 
85. In the Americas there are significant disparities in consumption levels of anxiolytics, as shown 
in figure 22. Apart from Argentina, the United States and Uruguay, which consumed on average 
more than 20 S-DDD of anxiolytics per thousand inhabitants per day between 2007 and 2009, six 
countries (Brazil, Canada, Chile, Cuba, Guyana and Paraguay) consumed between  
10 and 20 S-DDD per thousand inhabitants per day, and five countries consumed between 5 and  
10 S-DDD per thousand inhabitants per day. The great majority of countries and territories in the 
region (70 per cent) consumed less than 5 S-DDD of anxiolytics per thousand inhabitants per day. 
The high consumption levels observed for Argentina and Uruguay, which might indicate excessive 
availability and non-implementation of the prescription requirements foreseen by the  
1971 Convention, may be related to the very high consumption of anorectics in the subregion. 
 
Figure 21. Oceania (selected countries and territories): average consumptiona of 
benzodiazepines (anxiolytics), 1997-1999 and 2007-2009 
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a Approximate consumption calculated by the Board. 
 
 
Benzodiazepine-type sedative-hypnotics 
 
86. Among all the regions, calculated consumption levels of benzodiazepine-type sedative-
hypnotics were consistently highest in Europe, as shown in figure 23. However, consumption of 
benzodiazepine-type sedative-hypnotics decreased in many countries in Europe and elsewhere in 
much more pronounced fashion than in the case of anxiolytics, from the levels observed a decade 
before, reflecting changes in the types of benzodiazepines that were prescribed in medical practice. 
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Figure 22. Americas (selected countries and territories): average consumptiona of 
benzodiazepines (anxiolytics), 1997-1999 and 2007-2009 
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Figure 23. All regions: average consumptiona of benzodiazepines (sedative-hypnotics),  
1997-1999 and 2007-2009 
 
0
2
4
6
8
10
12
14
16
18
20
22
24
Europe Asia Oceania Americas Africa
S
-D
D
D
 p
e
r 
1
,0
0
0
 i
n
h
a
b
it
a
n
ts
 p
e
r 
d
ay
1997-1999 2007-2009
 
a Approximate consumption calculated by the Board. 
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87. In Europe, as shown in figure 24, in the period 2007-2009 average consumption levels of 
benzodiazepine-type sedative-hypnotics exceeded 10 S-DDD per thousand inhabitants in  
13 countries (about 30 per cent of the region), and in another 8 countries (Andorra, Croatia, Greece, 
Ireland, Malta, Norway, Serbia and United Kingdom, accounting together for 18 per cent of the 
region) the corresponding consumption levels exceeded 5 S-DDD per thousand inhabitants. 
Countries in Western Europe showed the highest consumption levels in the region of this group of 
benzodiazepines. 
 
 
88. In Africa, during the period 2007-2009 only Mauritius and South Africa showed an  
average calculated consumption of sedative-hypnotics higher than 1 S-DDD per thousand 
inhabitants. For five other countries (Cape Verde, Libyan Arab Jamahiriya, Namibia, Nigeria  
and Seychelles), consumption was between 0.1 and 1 S-DDD per thousand inhabitants per day.  
In five countries (Angola, Chad, Côte d’Ivoire, Ghana and Zambia) consumption levels were  
between 0.03 and 0.1 S-DDD per thousand inhabitants per day, whereas in all other countries and 
territories (82 per cent of the region) less than 0.03 S-DDD per thousand inhabitants per day was 
consumed. 
 
 
 
 
 
Figure 24. Europe (selected countries): average consumptiona of benzodiazepines  
(sedative-hypnotics), 1997-1999 and 2007-2009 
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Figure 25. Africa (selected countries): average consumptiona of benzodiazepines  
(sedative-hypnotics), 1997-1999 and 2007-2009 
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Figure 26. Asia (selected countries and territories): average consumptiona of benzodiazepines 
(sedative-hypnotics), 1997-1999 and 2007-2009 
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89. In Asia, consumption levels of benzodiazepine sedative-hypnotics tend to be very low, except in 
Israel and Japan, which are the two countries in Asia with the largest populations of elderly people. 
The high consumption levels observed in Japan might also reflect inappropriate prescribing patterns 
and associated abuse. In the period 2007-2009, apart from Israel and Japan, four countries (Bahrain, 
China, Republic of Korea and Singapore) had consumption levels of more than 1 S-DDD of this 
group of benzodiazepines per thousand inhabitants per day, whereas the majority of countries and 
territories in the region (88 per cent) had levels of less than 1 S-DDD per thousand inhabitants per 
day. 
 
90. In Oceania, in the period 2007-2009, only Australia and New Zealand had an  
average calculated consumption level of benzodiazepine-type sedative-hypnotics above  
1 S-DDD per thousand inhabitants per day. Six other countries and territories had consumption 
levels of at least 0.01 S-DDD of this group of benzodiazepines per thousand inhabitants per day, as 
shown in figure 27. Although Fiji, the Marshall Islands, Papua New Guinea and Vanuatu imported 
and used benzodiazepine-type sedative-hypnotics, their calculated consumption levels were less than 
0.01 S-DDD per thousand inhabitants per day. 
 
 
Figure 27. Oceania (selected countries and territories): average consumptiona of 
benzodiazepines (sedative-hypnotics), 1997-1999 and 2007-2009 
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a Approximate consumption calculated by the Board. 
 
91. In the Americas, in the period 2007-2009, Cuba and Uruguay had consumption levels averaging 
more than 10 S-DDD of benzodiazepine-type sedative-hypnotics per thousand inhabitants per day. 
Three countries (Canada, Paraguay and United States) had levels between 2 and 10 S-DDD per 
thousand inhabitants per day, and five countries and one territory (Argentina, Brazil, Chile, Panama, 
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Venezuela (Bolivarian Republic of) and Netherlands Antilles) had levels between 1 and 2 S-DDD per 
thousand inhabitants per day. The great majority of countries and territories in the region  
(80 per cent) had consumption levels of less than 1 S-DDD of benzodiazepine-type sedative-
hypnotics per thousand inhabitants per day. 
 
 
Figure 28. Americas (selected countries and territories): average consumptiona of 
benzodiazepines, 1997-1999 and 2007-2009 
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92. As affirmed in Commission on Narcotic Drugs resolution 53/4, on promoting adequate 
availability of internationally controlled licit drugs for medical and scientific purposes while 
preventing their diversion and abuse, the balance between adequate availability of these drugs  
and prevention of their diversion and abuse is at the core of the international drug control 
conventions. While in the absence of indicators of appropriate use it is at present not possible to 
determine what appropriate consumption levels would be in individual countries, let alone at the 
global level, it is possible to identify consumption levels that appear to be much too low or 
disproportionately high.  
 
93. In the case of countries with nil or practically nil consumption levels, such indicators for 
adequate levels are not required, as there can be no doubt as to the inadequacy of availability. The 
Board considers all levels of consumption of narcotic drugs below 200 S-DDD per million inhabitants 
per day inadequate. However, this does not imply that levels above 200 S-DDD can be considered 
adequate as the determination of whether availability of internationally controlled substances 
required for treatment is sufficient depends on the specific morbidity data.  
 
94. It may be of help to compare consumption levels between countries with similar levels of socio-
economic development to determine whether a country’s per capita consumption of certain drugs is 
in line with the levels prevalent in comparable countries. However, this method has two 
shortcomings. Low levels of consumption of internationally controlled substances are prevalent in 
certain regions. The fact that the majority of countries in a region record the same inadequately low 
levels of consumption does not make those levels adequate, but only indicates that most of the 
countries in the region face the same problem. On the other hand, disproportionately high levels of 
consumption of certain substances in a number of countries with comparable levels of  
socio-economic development do not make these consumption levels adequate. They could also 
indicate that prescription levels in all of those countries may be too high, and there could be a variety 
of reasons for this. 
 
95. At present, therefore, circumstantial indicators are used to support other indicators of whether 
consumption levels are too low or too high. Reports on untreated patients and on difficulties in 
obtaining required medications indicate serious impediments to availability. Reports on diversion of 
internationally controlled substances from domestic distribution channels, on large-scale smuggling 
of such substances, on trafficking and on significant abuse might indicate availability of 
internationally controlled substances above levels required for sound medical practice. 
V Achieving a balance between ensuring availability of internationally controlled 
substances for medical and scientific purposes 
and preventing their diversion and abuse 
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A. Impediments to availability of opioid analgesics 
 
96. The level of consumption of opioid analgesics in a country is generally correlated with its level 
of socio-economic development. There are a variety of factors determining why specific countries are 
found to have the highest levels of consumption of opioid analgesics in their region, including good 
reporting to and cooperation with the Board. 
 
97. The Board has on a number of occasions drawn the attention of Governments to the causes of 
limited availability of opioids under international control. The causes include regulatory, attitudinal, 
knowledge-related, economic and procurement-related problems that adversely affect availability. In 
a recent survey conducted by the Board24 on impediments to the availability of opioids for medical 
needs,25 a majority of Governments reported that attitude- and knowledge-related impediments — 
namely, addiction-related concerns among health-care professionals and patients and insufficient 
training for health-care professionals — continued to be the main factors contributing to the 
underuse of opioids. Unduly restrictive laws and burdensome regulations were also commonly 
perceived as playing a significant role in limiting the availability of opioids. A smaller number of 
Governments reported that difficulties involving distribution and supply and the high cost of opioids 
were major obstacles to making opioids adequately available. The most important impediments listed 
by countries were concerns about addiction, reluctance to prescribe or stock and insufficient training 
for professionals. The ranking of importance of the various impediments as indicated by countries 
responding to the survey is shown in figure 29. 
 
Figure 29.  Main factors affecting the availability of opioids for medical needs 
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Note: The results shown in the figure are based on replies submitted by countries and territories in response to a specific 
multiple-choice question. They could choose one or more responses. 
__________________ 
24 The survey was carried out by means of the questionnaire on which figure 29 is based. 
25 Report of the International Narcotics Control Board on Follow-up to the Twentieth Special Session of the General Assembly 
(United Nations publication, Sales No. E.09.XI.7). 
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98. In many countries with low consumption levels for opioids, the availability of opioids is 
influenced by a combination of regulatory, knowledge-related and economic factors. Those factors 
are clearly not independent of one another; for example, it may be more difficult to bring about 
regulatory reforms in a country where concerns about drug addiction are pervasive among 
policymakers and health-care professionals. Overcoming those impediments therefore requires a 
multifaceted approach and the participation of a broad range of stakeholders from the relevant 
governmental regulatory bodies, health-care professionals and non-governmental organizations 
active in the field of health care. 
 
99. France has successfully developed and implemented a multifaceted programme to ensure the 
adequate availability of opioid analgesics for the treatment of pain. Over the past decade, per capita 
consumption of opioid analgesics used in the treatment of moderate and severe pain has increased 
more than fivefold in France, making it one of the countries with apparently adequate and 
appropriate levels of consumption of opioid analgesics under international control.  
 
100. After it was recognized that in France the level of consumption of analgesics was too low and 
pain was not being adequately treated in the health-care system, legislative and policy changes were 
introduced to promote the implementation of successive national action plans to combat pain, 
starting in 1989. Ensuring that health-care professionals are adequately educated about the treatment 
of pain has been an important element of each action plan. To that end, modules on pain treatment 
and palliative care were introduced into the curricula of medical and nursing schools, and 
programmes about pain treatment were developed to provide continuous training for personnel in 
health-care facilities. At the same time, a number of regulatory reforms made it less difficult for 
opioids to be procured, prescribed and dispensed. Examples of such reform measures that have had a 
significant impact on the effective treatment of pain include extending the validity of prescriptions 
for opioid analgesics from 7 to 28 days and allowing nurses to administer opioids in the absence of a 
doctor. While promoting the consumption of opioids for the treatment of pain, the Government of 
France has, at the same time, established mechanisms to monitor and prevent the abuse and diversion 
of those substances. All of the above activities remained within the frame of the international 
conventions. 
 
101. While increases in consumption levels for opioid analgesics may be easier to achieve in 
countries that, like France, have adequate resources for health care, such improvements are also 
possible in countries with more limited resources, such as Uganda. Over the past 10 years, morphine 
consumption in Uganda has increased steadily, as a result of the expansion of a programme that 
provides home-based palliative care to patients throughout the country. In Uganda, as in France, key 
factors in the successful implementation of this approach include the commitment of the 
Government to making relief from pain a health-care priority and the education of health-care 
professionals about the use of opioids and palliative care. Another important step towards ensuring 
access to morphine for patients in a range of health-care settings has been the introduction of legal 
reforms allowing nurses to prescribe morphine. That is an example of the kind of task-shifting 
recommended by WHO26 to increase access to health-care services in situations where there is a 
shortage of health-care workers. Developing systems for the reliable procurement of morphine and 
__________________ 
26 World Health Organization, Task Shifting: Rational Redistribution of Tasks among Health Workforce Teams — Global 
Recommendations and Guidelines (Geneva, 2008). 
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making it available for oral administration, at a low cost, have also been essential to efforts to broaden 
access to that drug. Again all of the activities remained within the frame of the international 
conventions. 
 
102. The examples of France and Uganda show that increased consumption of opioid analgesics can 
be achieved with strong governmental support through a multipronged strategy to remove 
impediments to their availability. Although many countries in Europe have consumption levels for 
opioids under international control that are comparable to that of France, a number of countries, 
including many in Eastern Europe, currently have levels of opioid consumption that are much  
lower than the level reported by France 10 years ago. For the majority of the people in many countries 
in Africa, access to low-cost oral morphine is practically non-existent. Unfortunately, inadequate 
access to opioids remains a reality in a large number of countries not only in Africa and  
Eastern Europe but in all regions. The Board calls upon the Governments of those countries  
to take determined steps to ensure adequate access to opioid analgesics and to reinforce the 
regulatory agencies, which is a key to adequate access to controlled drugs and their appropriate  
use. To that end, Governments should consider the recommendations contained in the  
1995 special report of the Board on the availability of opiates for medical needs,27 and in chapter I of 
the Board’s report for 1999.  
 
103. The Board notes with appreciation that in the past few years, the Governments of a number of 
countries, including Georgia, Guatemala, Panama, Serbia and Viet Nam, have introduced policy 
reforms aimed at ensuring adequate access to opioid analgesics. The Governments of those countries 
and others that are in the initial stages of developing strategies for improving the availability of 
opioids should provide strong support for the implementation of those strategies. Mechanisms 
should be in place for monitoring the implementation and the long-term effectiveness of policies to 
improve access to opioids. 
 
104. The Board is of the opinion that there is an urgent need for some Governments to take specific 
measures to ensure that their populations have adequate access to opioid-based medications in 
accordance with the international drug control conventions. In particular, Governments of countries 
in which opioid consumption is below 100 S-DDD per million inhabitants per day and Governments 
of countries with no opioid consumption at all should immediately take appropriate action to ensure 
access to such medications. The key element is an effective regulatory body. It is not admissible that 
large parts of the world remain seriously undersupplied with medicines that are necessary to alleviate 
the pain and suffering of patients. 
 
105. The Board calls the attention of Governments to the fact that accurate estimation of 
requirements for internationally controlled substances is essential to ensure the adequate availability 
of those substances for medical and scientific purposes. Poor estimation of those requirements can 
lead to many problems in the use of controlled substances in the health-care system, such as 
shortages, irrational prescribing, distortion of demand and low cost-effectiveness; it can also lead to 
surpluses and increased risk of diversion of controlled substances. Proper use of the system of 
estimates for narcotic drugs and the system of assessments for psychotropic substances is important 
to ensure adequate availability of internationally controlled substances. For this purpose, national 
__________________ 
27 Availability of Opiates for Medical Needs (see footnote 8 above). 
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competent authorities need to ensure that health-service providers can easily communicate their 
requirements to them. 
 
 
 
B. Availability of internationally controlled substances above levels 
required for sound medical practice 
 
 
106. Lack of availability of narcotic drugs and psychotropic substances may deprive patients of their 
fundamental rights and the opportunity to have relief from physical pain and from suffering due to 
mental illness. On the other hand, excessive availability of these drugs can lead to diversion and abuse 
and subsequently to drug dependence. Over recent years the Board has noted with increasing concern 
that the abuse of internationally controlled substances, diverted into illicit channels at various stages 
of their distribution, continues to be widespread in many countries and has in some countries 
reached or overtaken the levels of abuse of illicit drugs.  
 
107. In a number of countries, the abuse of pharmaceuticals containing controlled substances is 
second only to the abuse of cannabis. The pharmaceutical preparations diverted and abused contain 
various opioids, benzodiazepines and amphetamine-type stimulants. Among opioids, diversion of 
preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, 
methadone, morphine, oxycodone and trimeperidine account for the largest quantities diverted. 
Among the psychotropic substances, alprazolam, buprenorphine, diazepam, flunitrazepam, 
phenobarbital and phentermine are the most often diverted and abused substances.  
 
108. Data collected by Governments suggest that abuse patterns are related to excessive overall 
availability of the pharmaceutical preparations containing these substances. In particular, countries 
with already elevated levels of consumption of narcotic drugs and psychotropic substances  
that experience further significant increases should be vigilant to determine whether these increases 
are related to actual medical requirements or to their misuse and abuse. Changing drug prescription 
and drug consumption patterns is usually a slow process, and new drug consumption habits develop 
over a period of years. New fashions in drug abuse, on the other hand, develop quite fast, in particular 
when the drugs of abuse show the same effect as previously abused illicit drugs but are easier  
to obtain. A culture of widespread and excessive availability of pharmaceuticals that have effects 
similar to those created by illicit drugs will result in the increasing substitution of these 
pharmaceuticals for illicit drugs. Reversing such a trend is difficult and requires efforts, as the abused 
pharmaceuticals will remain available. This explains why, in countries with excessive availability, the 
non-medical use of pain relievers, tranquillizers, stimulants or sedatives has become the fastest-
growing drug problem.  
 
109. In most countries the problem of abuse of prescription drugs has received less attention  
from drug control regulators than abuse of illicit drugs. The systematic collection of data on 
prescription drug abuse in household surveys is at present carried out only in the United States, 
which means that reliable data on the extent of such abuse are limited to that country. The problem 
is, however, not restricted to the United States. Abuse of prescription drugs is reported from all 
regions in the world.  
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110. Abuse of prescription drugs can be as dangerous as abuse of illicit drugs. In particular, the share 
of prescription opioids in cases of death related to overdose has significantly increased. This has, 
unfortunately, been overlooked by the general public for a long time. Over the last decade the number 
of cases of death related to prescription drug abuse has risen significantly, overtaking in some 
countries the number of cases of death from overdose related to illicit drugs. However, it was only 
because the deaths of several prominent entertainers were related to abuse of prescription drugs that 
the media and the broader public have taken note of the dangers of prescription drug abuse. Action 
should be taken, however, before such high levels of abuse of prescription drugs are reached. Since 
excessive availability is often the first step towards increasing abuse of prescription drugs, drug 
control regulators need to be vigilant with regard to high consumption levels of narcotic drugs and 
psychotropic substances.  
 
 
111. Increasing abuse of prescription drugs has led to rising levels of poly-drug addiction, combining 
licitly manufactured medicines and illicit drugs or several medicines containing internationally 
controlled substances. Equally, the abuse of combination products manufactured by the 
pharmaceutical industry or prescription formulas prepared in pharmacies combining several 
internationally controlled substances is increasing.  
 
 
112. The Board encourages all Governments to identify unusual trends in consumption levels for 
narcotic drugs and psychotropic substances and to take remedial action, if required. In the absence of 
accepted norms for adequate consumption, Governments may wish to analyse past trends and 
compare their national consumption levels with those of other countries at a similar level of socio-
economic development.  
 
 
113. Such comparisons could be carried out on the basis of the tables on the consumption of opioid 
analgesics and the various groups of psychotropic substances published by the Board in its technical 
report on narcotic drugs and its technical report on psychotropic substances. The Governments of 
countries with particularly high or rising levels of consumption of narcotic drugs and psychotropic 
substances should monitor the situation closely, determine whether their territories are being used for 
illegally operating Internet pharmacies, identify possible overprescribing or any other unprofessional 
practices among medical professionals and ensure that domestic distribution channels are adequately 
controlled. All Governments should implement the recommendations of WHO on the rational 
prescribing of drugs and take measures to promote sound medical practices.28  
 
 
114. To prevent substances under international control from being diverted in one country and 
subsequently smuggled into another, Governments should harmonize at the regional and subregional 
levels measures taken to reduce excessive consumption levels, so that the efforts made in one country 
will not result in problematic consumption patterns shifting to neighbouring countries. 
 
 
115. However, the use of certain groups of substances may not differ only between countries with 
comparable levels of socio-economic development in different regions, but also between countries in 
__________________ 
28 “Promoting rational use of medicines: core components”, WHO Policy Perspectives on Medicines, No. 5,  
September 2002. Available at http://whqlibdoc.who.int/hq/2002/WHO_EDM_2002.3.pdf. 
ACHIEVING A BALANCE: ENSURING AVAILABILITY OF CONTROLLED SUBSTANCES AND PREVENTING THEIR DIVERSION AND ABUSE 
 
49 
the same region, owing to cultural and demographic factors. For example, significant  
cross-national and country-specific variations indicate considerable variances in medical practice 
between otherwise similar countries, and sometimes even within countries.  
 
116. A persistent difference in consumption of internationally controlled substances is seen in  
the regional preferences for groups of psychotropic substances in Europe and in North America,  
two regions with similar levels of socio-economic development. While Europe records the  
world’s top use of benzodiazepines, North America records the top consumption of performance-
enhancing stimulants. This may imply cultural differences, but may also be related to  
demographics, as benzodiazepines are taken mostly by the older segments of the population, while 
performance- and body shape-enhancing drugs are consumed to a larger extent by adolescents and 
younger adults. 
 
117. The channels of supply of abused prescription drugs vary, but, in principle, once they have  
left the officially controlled supply channels they are to be found in a “parallel market” of  
sometimes significant dimensions. In many countries, unregulated drug markets called “street 
markets” operate in parallel to or often in the absence of licensed pharmacies. The reasons for 
purchasing medications on such street markets are often related to economic factors or to an 
insufficient supply through official channels. Illegally operating Internet pharmacies are another kind 
of parallel market. As in street markets, customers can obtain internationally controlled drugs such as 
benzodiazepines, opioids, stimulants and barbiturates without a prescription. The supplies for these 
markets are often diverted or stolen products, or unregistered, substandard or counterfeit 
medications.  
 
118. Depending on the country, the reasons for utilizing unregulated markets vary. They include 
limited access to health-care facilities, lower cost of drugs, which is often related to the fact that they 
are substandard or counterfeit products, overly stringent prescription requirements, the desire to 
obtain drugs without medical records to preserve privacy or demand for prescription drugs for abuse 
purposes. 
 
119. All Governments should apply the International Narcotics Control Board guidelines for the 
control of Internet pharmacies,29 because in some countries such pharmacies represent the principal 
channel for the illicit distribution of internationally controlled substances. 
 
 
 
C. Ensuring adequate availability in emergency situations 
 
 
120. Emergency situations in the wake of natural or man-made disasters may lead to a sudden and 
acute need for medicines containing controlled substances. Such a situation arose following the 
devastating earthquake in Haiti in January 2010. Controlled substances such as morphine and 
pentazocine were urgently required to provide medical care for the large number of people who had 
been injured in the earthquake. 
__________________ 
29 Guidelines for Governments on Preventing the Illegal Sale of Internationally Controlled Substances through the Internet (United 
Nations publication, Sales No. E.09.XI.6). 
REPORT ON THE AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS 
 
50 
121. Humanitarian relief agencies have often found it difficult to rapidly obtain medicines 
containing controlled substances for medical care in emergency situations, in part because of the 
control measures exerted over the international movement of such medicines. The administrative 
requirements that must be fulfilled under normal circumstances to authorize the import and export 
of controlled substances slow down the supply of urgently needed medicines to disaster areas. This 
problem is compounded if competent national authorities in the importing countries are no longer 
functioning.  
 
122. To address that issue, WHO, in consultation with the Board, prepared the Model Guidelines for 
the International Provision of Controlled Medicines for Emergency Medical Care.30 The Guidelines 
provide a simplified procedure for the export of medicines containing controlled substances to be 
handled by reputable humanitarian relief agencies. Soon after the earthquake in Haiti, the Board sent 
letters to all Governments and selected humanitarian relief agencies to remind them about the 
simplified procedures contained in the Guidelines.  
 
123. Because emergency situations come about suddenly, competent authorities should be prepared 
to use the simplified procedures contained in the Guidelines to expedite the supply of controlled 
medicines as soon as the need arises. The Board invites Governments and humanitarian relief 
agencies to bring to its attention any problems encountered in making deliveries of controlled 
medicines in emergency situations. Governments may wish to include in their special stocks of 
narcotic drugs and psychotropic substances quantities to meet the need for such substances in the 
event of an emergency situation.  
 
__________________ 
30 World Health Organization, document WHO/PSA/96.17. 
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124. The International Narcotics Control Board has frequently confirmed that the underlying 
principles of the international drug control treaties provide the mechanism to ensure availability of 
narcotic drugs and psychotropic substances for medical and scientific requirements while at the same 
time preventing their inappropriate use and abuse. Ensuring availability of narcotic drugs and 
psychotropic substances and preventing their diversion are not contradictory goals; in fact, action to 
achieve these two objectives can be in synergy if measures are correctly and fully implemented. The 
proper interpretation of these two complementary aims is accepted by an ever-wider range of 
countries. However, substantial progress is still required in a number of countries.  
 
125. The Board notes that, in response to previous recommendations on availability of narcotic 
drugs, a significant number of Governments have increased their estimates to meet medical demand, 
issued national policies to improve medical use of narcotic drugs, supported educational programmes 
and examined their health-care systems, laws and regulations for impediments. There have been 
improvements in the adequacy of supply of certain narcotic drugs and psychotropic substances in 
many countries, but there have been setbacks in others. While the most significant improvements are 
recorded in highly developed countries, the setbacks, unfortunately, have occurred mostly in the 
regions that 20 years ago had the lowest levels of availability of internationally controlled substances.  
 
126. As shown in the Board’s analysis, a large number of countries in many regions continue to 
record inadequate levels of availability of internationally controlled substances. Africa remains the 
region with the largest number of countries recording little or no availability. Other regions where the 
situation has not improved, and in certain cases worsened, are Central America and the Caribbean 
and South Asia. However, even in regions with overall increasing levels of availability, countries 
remaining at the lower margin in terms of consumption of controlled substances record inadequately 
low levels of availability.  
 
127. Among the countries with particularly low levels of availability are a number of countries with 
large populations; thus, large parts of the world population have no access to narcotic drugs and 
psychotropic substances. Also, even if countries have recorded improvements, the improvements 
may not have led to levels that could be considered adequate, because of low starting levels. In spite of 
the progress made towards meeting treaty objectives, relatively few countries in the world have an 
adequate drug supply management system and working mechanisms that ensure reliable,  
needs-based assessments, equitable availability and cost-effectiveness.  
 
128. According to the analysis of the Board, deficiencies in drug supply management remain 
attributable to lack of financial resources, inadequate infrastructure, the low priority given to health 
VI Conclusions and recommendations 
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care, weak government authority, inadequate education and professional training, and outdated 
knowledge, which together affect the availability of not only controlled drugs but all medicines. 
 
129. Substantial improvement in the availability of narcotic drugs and psychotropic substances is 
linked to progress in the availability of medicines in general, particularly in countries with limited 
resources for health, where growing economic disparities, pressing basic needs and poor 
infrastructure are the principal barriers to any lasting improvement. During recent years 
international awareness has increased, and efforts to facilitate the supply of licit drugs to 
underdeveloped areas are carried out by intergovernmental and non-governmental organizations. 
However, despite growing global awareness of the prevailing unsatisfactory situation, a considerable 
number of countries continue to show no appreciation of the problem itself or of the relative ease 
with which efficient treatment can be provided.  
 
130. It appears that a number of countries have not yet recognized that adequate availability of 
medicines, including narcotic drugs and psychotropic substances, is an essential part of their 
responsibility towards their populations. Negligence towards this responsibility is shown when 
countries do not even estimate their requirements and appear to have no knowledge about the 
quantities of certain drugs their populations would require for medical treatment. In other countries, 
where such negligence is not observed, other obstacles continue to prevail, including outdated 
restrictive regulations and, more frequently, uninformed interpretations of otherwise correct 
regulations, misguided fears and ingrained prejudices about using opioids for medical purposes. 
 
131. The Board has always emphasized that the efforts to limit the use of narcotic drugs and 
psychotropic substances to medical and scientific purposes must not adversely affect their availability 
for such purposes. On the other hand, increasing the use of certain controlled drugs for legitimate 
medical purposes needs thorough monitoring. Careful attention has to be given to ensuring the 
legitimate absorption capacity of countries and the proper functioning of safeguard mechanisms in 
order to minimize misuse and leaks in the system. The Board is of the opinion that a well-educated 
and functioning control-system administration is a prerequisite for ensuring availability, as it will be 
able to determine the quantities required and will identify shortages and problems in distribution. A 
functioning control-system administration will also be a responsible partner for cooperation with 
professional and consumer associations.  
 
132. The overall goal of a well-functioning national and international system for managing the 
availability of narcotic drugs and psychotropic substances should be to provide relief from pain and 
suffering by ensuring the safe delivery of the best affordable drugs to those patients who need them 
and, at the same time, to prevent the diversion of drugs for the purpose of abuse. To ensure this, 
Governments need to fulfil the following essential tasks: 
 
 
Recommendations on availability of narcotic drugs and psychotropic substances  
 
 (a) Governments should assess the actual requirements of the national health systems for 
internationally controlled substances; calculate their annual requirements for such substances and 
furnish the Board with timely estimates for narcotic drugs and assessments for psychotropic 
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substances. In case national requirements are at the lower margin of levels of requirements in the 
region, Governments may need to critically examine their methods for assessing their medical 
requirements for narcotic drugs and psychotropic substances;  
 
 (b) Governments should identify impediments to availability of narcotic drugs and 
psychotropic substances (policy, regulatory, administrative) and take detailed, step-by-step measures 
to remove those impediments;  
 
 (c) Governments should establish a system to collect information from medical facilities that 
provide care for the mentally ill, addicts and surgery, cancer and other patients, from organizations 
that are working to improve the appropriate use of narcotic drugs and psychotropic substances, and 
should establish groups of knowledgeable individuals to assist in obtaining information about 
changing medical needs; they should also make use of available guidelines on assessing the actual 
requirements for narcotic drugs and psychotropic substances for their country; 
 
 (d) Once a country has reached an appropriate level of consumption of narcotic drugs and 
psychotropic substances, Governments should add to their annual estimates of requirements for 
narcotic drugs and assessments for psychotropic substances a margin to allow for the possibility of 
increased consumption from such general causes as population growth, evolution of health services 
and trends in the incidence of diseases and their treatment and, if need be, should add an even greater 
margin in countries or territories where there is rapid economic and social development or rapid 
expansion of the medical use of drugs, including the introduction of new formulations or drugs; 
 
 (e) Governments that experience interruptions in the supply of narcotic drugs and 
psychotropic substances because of delays in importation or for other reasons should examine the 
situation and develop a system to accomplish in a timely manner the steps involved, such as issuing 
licences, arranging for payment, carrying out paperwork, transporting the drugs, taking the drugs 
through customs and distributing the drugs to medical facilities; 
 
 (f) Governments should determine whether their national narcotics laws contain elements of 
the 1961 Convention as amended by the 1972 Protocol that take into account the fact that the medical 
use of narcotic drugs continues to be indispensable for the relief of pain and suffering and the fact 
that adequate provision must be made to ensure the availability of narcotic drugs for such purposes 
and to ensure that administrative responsibility has been established and that personnel are available 
for the implementation of those laws; 
 
 (g) Governments should determine whether there are undue restrictions in national narcotics 
laws, regulations or administrative policies that impede the prescribing or dispensing of, or needed 
medical treatment of patients with, narcotic drugs or psychotropic substances, or their availability 
and distribution for such purposes, and, should this be the case, make the necessary adjustments; 
 
 (h) To promote adequate availability of psychotropic substances globally and in specific 
countries pursuant to Commission on Narcotic Drugs resolution 53/4, Governments should collect 
the most reliable statistical data on the consumption of psychotropic substances and submit that 
information to the Board in timely fashion; 
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 (i) Governments should fully cooperate with the Board in ensuring adequate availability of 
narcotic drugs and psychotropic substances; they should examine their medical needs for narcotic 
drugs and psychotropic substances, as well as the impediments to their availability, advise the  
Board of the results of those efforts and inform the Board if it can be of assistance; they should also 
inform the Board about progress and needs concerning implementation of the present 
recommendations;  
 
 
Recommendations on appropriate use 
 
 (j) Governments should ensure the correct education and training of health professionals and 
should inform health professionals about the WHO analgesic method for cancer pain relief; they 
should communicate with health professionals about the legal requirements for prescribing and 
dispensing narcotic drugs and psychotropic substances and should provide an opportunity to discuss 
mutual concerns;  
 
 (k) Governments should ensure that comprehensive curricula on substance abuse and 
rational use of psychoactive drugs are used in relevant faculties of universities, medical, 
pharmaceutical and nursing schools and other health-care institutes;  
 
 (l) Governments should stimulate, through regulation and monitoring, ethical behaviour in 
drug marketing; they should ensure high professional standards in therapy (diagnosis, deciding on 
therapy, prescribing);  
 
 (m) Governments should educate the public in the appropriate use of narcotic drugs and 
psychotropic substances and in the correct use of pharmacotherapy with other therapeutic options, 
and should enlist in this effort the active participation of professional organizations and consumer 
associations;  
 
 (n) Governments should establish a comprehensive registration and authorization system and 
select carefully and support safer and more cost-effective drugs and reliable alternative treatment 
modalities;  
 
 (o) Governments should also encourage the development and use of better and safer 
therapeutic agents (with little or no dependence potential) to replace medicines with limited  
efficacy and safety. Countries experiencing abuse problems with regard to combination products or 
prescription formulas have a responsibility to make sure that action is taken to prevent such abuse; 
 
 
Recommendations on national control systems 
 
 (p) Governments should endeavour to keep the supply and consumption of internationally 
controlled substances under close supervision. Experience has shown that particular attention needs 
to be given to adequate legislation and correct administrative arrangements, adapted, as required, to 
new trends and developments;  
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 (q) Governments should establish a sufficient degree of government authority and regulatory 
control over the national drug supply, including the control of narcotic drugs and psychotropic 
substances;  
 
 (r) Governments should conduct inspections of manufacturers, exporters, importers and 
wholesale and retail distributors, as well as of stocks and records, and take appropriate action against 
those who fail to comply with applicable legal requirements and professional codes of conduct. 
Activities of market intermediaries such as brokers must be regulated, as appropriate;  
 
 (s) Governments need to ensure adequate financial and human resources for their drug 
regulatory authorities and other agencies and provide capacity-building to their staff; 
 
 (t) Governments need to implement effective policies to combat counterfeit drugs and 
provide a comprehensive legal framework to make trading in counterfeit products a serious criminal 
offence; exporting countries must regulate the process with a view to preventing the export of drugs 
that are counterfeit or of poor quality;  
 
 (u) Governments should be aware and make the best use of the Model Guidelines for the 
International Provision of Controlled Medicines for Emergency Medical Care; 
 
 
Recommendations on prevention of diversion and abuse 
 
 (v) Governments should enforce existing legislation to ensure that narcotic drugs and 
psychotropic substances are not illegally manufactured, imported or exported and are not diverted to 
the unregulated market;  
 
 (w) Governments should collect data on the abuse of prescription drugs in a more systematic 
manner and include in their national surveys on drug abuse, as far as possible, pharmaceuticals 
containing narcotic drugs and psychotropic substances, by including either specific groups of 
substances or specific narcotic drugs and psychotropic substances, as required;  
 
 (x) Considering the international nature of the problem and to complement the efforts of law 
enforcement in individual countries in the above-mentioned areas, Governments, as well as regional 
and international organizations, should develop intergovernmental agreements for effective joint 
operations and arrangements and standards to be applied at the regional level;  
 
 (y) Governments should take prompt and effective action to implement previous 
recommendations of the Board on Internet trading and on the misuse of the mail for smuggling of 
internationally controlled substances. 
 
133. To achieve the goal of adequate availability of narcotic drugs and psychotropic substances 
globally, support from the world community is required. Progress in countries with low levels of 
consumption of such drugs is usually gradual. Prevailing market conditions and the present supply 
system do not make it possible to ensure the availability of needed medicines in low-income 
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countries. Economic and financial conditions in such countries and insufficient health-care 
infrastructure are impediments that cannot be overcome by those countries alone. Progress can be 
achieved only on the basis of a more humanitarian approach that is in line with the treaty system. 
Such an approach in selected countries may include the provision of assistance in establishing more 
reliable baseline estimates and assessments of medical needs and consultations with potential 
suppliers under preferential conditions.  
 
134. The Board concludes that if the above recommendations are implemented, there will be 
significant additional progress towards ensuring adequate availability of narcotic drugs and 
psychotropic substances for medical and scientific purposes. The Board will continue its examination 
of the situation and will monitor responses to its recommendations. To support progress the Board 
will continue to:  
 
 (a) Monitor annual estimates for narcotic drugs and assessments for psychotropic substances 
submitted by Governments and initiate dialogue as necessary to identify unmet needs and ensure that 
annual estimates or assessments of requirements for narcotic drugs and psychotropic substances are 
neither overestimated nor underestimated; 
 
 (b) Ensure expeditious confirmation of supplementary estimates and processing of modified 
assessments for psychotropic substances submitted by Governments to assist them in coping with 
unforeseeable needs; 
 
 (c) Review on a regular basis national and international developments relevant to improving 
the availability of narcotic drugs and psychotropic substances for medical purposes, incorporating 
updated information and observations into its annual report; 
 
 (d) Encourage Governments to develop drug distribution systems that are well controlled and 
that will ensure availability of narcotic drugs and psychotropic substances to patients in medical 
facilities and in the community; 
 
 (e) Cooperate with UNODC to include in the model national legislation on the control of 
narcotic drugs and psychotropic substances provisions that recognize the obligation to ensure the 
adequate availability of narcotic drugs and psychotropic substances for medical and scientific 
purposes; 
 
 (f) Respond to the call of the Commission on Narcotic Drugs in the area of availability of 
internationally controlled substances and support the Commission in its efforts to remind parties to 
the 1961 Convention and the 1971 Convention of their obligations in this respect;  
 
 (g) Cooperate with WHO to assist Governments in developing adequately controlled drug 
distribution systems that are capable of providing narcotic drugs and psychotropic substances to 
patients in hospitals and in the community; 
 
 (h) Alert the international community to new trends in abuse of pharmaceutical preparations 
containing narcotic drugs and psychotropic substances; 
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 (i) Alert the international community to emerging new methods of trafficking of 
internationally controlled substances; 
 
 (j) Support Governments in implementing the provisions of the international drug control 
treaties and additional control measures, as requested by the Economic and Social Council, as well as 
the relevant guidelines of the Board. 
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Annex I 
 
Tables on consumption of opioid analgesics in regions 
 
Table 1 
Levels of consumption of narcotic drugs: average consumption of narcotic drugs, 2007-2009, by 
region per day 
(Defined daily doses for statistical purposes per million inhabitants per day) 
 
Region Codeine Fentanyl 
Hydro-
codone 
Hydro-
morphone Morphine Oxycodone Pethidine Others Total 
Americas  31 3 781 6 850  337  809 2 217  40  254 14 320 
North America  58 7 481 13 738  675 1 564 4 441  72  509 28 536 
South America  5  120  8  1  68  8  10  2  221 
Central America 
and the Caribbean 
<<  32  4 <<  16  4  8  1  65 
Oceania  70 2 727 <<  42 1 050 1 590  28  3 5 510 
Europe  32 3 707  6  104  398  288  11  689 5 236 
Asia  2  72  1 <<  14  7  5  4  105 
West Asia  2  123  - <<  8  8  7  7  155 
East and South-East 
Asia 
 3  102 <<  1  19  4  11  8  146 
South Asia <<  3  1  -  7 <<  1  4  17 
Africa  4  22 << <<  10 <<  3  11  50 
 
Note: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
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Table 2 
Levels of consumption of narcotic drugs 
 
A. Average consumption of narcotic drugs in North America, South America and Central 
America and the Caribbean, 2007-2009 
 (Defined daily doses for statistical purposes per million inhabitants per day) 
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North America 
1 1 1 United States 
of America 
<< 9 904 20 066  673 2 060 5 962  88  734 39 487 
2 2 2 Canada  783 9 432  253 2 909 2 080 4 932  151  92 20 632 
3 21 91 Mexicoa  -  74  -  1  9  1  -  -  85 
Regional average:  
North America 
 58 7 481 13 738  675 1 564 4 441  72  509 28 536 
South America 
1 3 20 Falkland 
Islands 
(Malvinas)a 
369 2 347  -  -  452  -  31 1 084 4 283 
2 6 52 Argentina  14  103  42  -  250  12  2  20  443 
3 8 55 Chile  69  198  -  -  108  5  7  1  388 
4 9 57 Colombia  -  188  34  4  42  24  1  -  295 
5 12 61 Brazil <<  139  -  -  59  3  17  -  218 
6 13 71 Uruguay  -  77  1  -  76  -  10  -  164 
7 23 97 Venezuela 
(Bolivarian 
Republic of ) 
 -  47  - <<  9  14  1  -  71 
8 25 105 Ecuador  -  50  -  -  7  5  -  -  62 
9 26 106 Suriname  27  12  -  -  18  -  4  -  61 
10 27 107 Peru  -  26  -  -  19  9  4  -  58 
11 31 119 Paraguay  -  28  -  -  2  -  8  -  38 
12 33 146 Guyana  2  4  -  -  3  -  1  -  10 
13 34 159 Bolivia 
(Plurinational 
State of) 
- <<  -  -  1  2  -  -  3 
Regional average: South 
America 
5 120 8 1 68 8 10 2 221 
Central America and the Caribbean 
1 4 29 Cayman 
Islands 
18 1 465 181 32 89 714 408 2 2 909 
2 5 41 Netherlands 
Antilles 
- 1 080 - - 82 2 20 45 1 229 
3 7 54 Turks and 
Caicos Islands 
2 133 - - 10 151 57 39 392 
4 10 58 Bahamas 8 8 - - 40 96 140 - 292 
5 11 59 Montserrat 223 << - - 14 - 35 - 272 
6 14 76 Trinidad and 
Tobagoa 
- 17 - - 42 - 78 - 137 
7 15 79 Panama - 104 - - 7 - 8 - 119 
8 16 83 Costa Rica - 41 - - 61 - 2 - 104 
9 17 84 Saint Lucia 29 1 4 - 21 - 36 - 91 
10 18 85 El Salvador - 48 3 - 4 19 16 - 90 
11 19 87 Cuba - 44 - - 36 - 6 2 88 
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12 20 89 Jamaica 2 14 - - 30 - 40 - 86 
13 21 91 Saint Vincent 
and the 
Grenadines 
1 5 - - 30 - 49 - 85 
14 24 103 Grenada 7 4 - - 14 - 31 7 63 
15 28 114 Guatemala - 16 21 - 4 4 3 << 48 
16 29 115 Dominica - 1 - - 7 - 38 - 46 
17 30 118 Nicaragua - 30 - - 7 2 << - 39 
18 32 129 Dominican 
Republic 
- 15 - - 8 1 << - 24 
19 35 165 Haiti << 1 - - 1 - << - 2 
Regional average:  
Central America and the 
Caribbean 
<< 32 4 << 16 4 8 1 65 
Average: Americas 31 3 781 6 850 337 809 2 217 40 254 14 320 
 
Notes: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
As at 1 November 2010, in North America, the following territory had not submitted any statistical forms for the three 
consecutive years in question: Bermuda; in Central America and the Caribbean, the following eight countries and territories 
did either not submit any statistical forms or did not provide any consumption data for the three consecutive years in 
question: Anguilla, Antigua and Barbuda, Aruba, Barbados, Belize, British Virgin Islands, Honduras and Saint Kitts and 
Nevis. 
a Calculation is based on data covering two years only. 
REPORT ON THE AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS 
 
62 
B. Average consumption of narcotic drugs in Oceania, 2007-2009 
 (Defined daily doses for statistical purposes per million inhabitants per day) 
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1 13 Australia  108 4 058 <<  64 1 381 2 367  31  4 8 013 
2 24 Norfolk 
Island 
 42 2 740  -  -  393  213  15  - 3 403 
3 32 New 
Caledonia 
 - 2 187  -  17  266  9  -  - 2 479 
4 33 New 
Zealand 
 -  637  - << 1 192  479  56 << 2 364 
5 36 Wallis and 
Futuna 
Islands 
 135  823  -  -  18  -  - 1 161 2 137 
6 38 French 
Polynesia 
 - 1 263  -  7  141  6  1  - 1 418 
7 40 Christmas 
Island 
 9  818  -  -  12  487  8  - 1 334 
8 51 Palau  34  2  485  -  16  -  27  -  564 
9 81 Cook 
Islandsa 
 -  -  -  -  41  -  66  -  107 
10 88 Tongaa  50  3  -  -  15  -  19  -  87 
11 111 Naurub  5  13  -  -  14  -  21  -  53 
12 120 Marshall 
Islandsb 
 -  7  -  -  15  -  11  -  33 
Papua New 
Guineab 
 1 <<  -  -  15  -  15  -  31 
13 123 
Vanuatub  8  12  -  -  11  -  -  -  31 
15 136 Samoa  -  1  -  -  7  -  7  -  15 
Regional average: Oceania  70 2 727 <<  42 1 050 1 590  28  3 5 510 
 
Notes: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
As at 1 November 2010, the following six countries and territories either had not submitted any statistical forms or had not 
provided any consumption data for the three consecutive years in question: Cocos (Keeling) Islands, Fiji, Kiribati, Micronesia 
(Federated States of), Solomon Islands and Tuvalu. 
a Calculation is based on data covering two years only. 
b Calculation is based on data covering one year only. 
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C. Average consumption of narcotic drugs in Europe, 2007-2009 
 (Defined daily doses for statistical purposes per million inhabitants per day) 
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1 3 Germany  1 12 772  41  615  619  836  14 4 421 19 319 
2 4 Austria  17 10 252  -  932 4 593  200  6  160 16 160 
3 5 Belgium  22 10 613  42  126  366  72  13 3 460 14 714 
4 6 Denmark  - 8 078  6  74 1 523 2 298  75  992 13 046 
5 7 Switzerland  98 7 649  67  232 1 238  717  80 2 963 13 044 
6 8 Iceland 4 818 5 607  -  48  919  249  8  841 12 490 
7 9 Gibraltar  - 10 714  -  -  325  37  15  44 11 135 
8 10 Netherlands  - 6 460  -  31  377  470  9  839 8 186 
9 11 Spain  - 7 702  -  53  180  107  22  8 8 072 
10 12 Finland  35 6 861  -  17  107 1 023  3  12 8 058 
11 14 Norway  16 5 284  6  12  810 1 225  32  241 7 626 
12 15 Luxembourg  3 5 266 <<  120  197  2  4 1 431 7 023 
13 16 Sweden  - 4 763 <<  200  584 1 074  3  192 6 816 
14 17 France  129 5 055  -  43 1 024  328  1  184 6 764 
15 18 Slovenia  59 4 726  -  172  761  308  6  236 6 268 
16 19 Ireland  - 4 413  2  111  269  525  24 << 5 344 
17 21 Greece << 4 217  - <<  14 <<  18  21 4 270 
18 22 United 
Kingdom 
 1 1 281 <<  36 1 114  914  33  276 3 655 
19 25 Hungary  24 2 925 <<  57  36  19  5  300 3 366 
20 26 Czech Republic  60 2 444  -  117  142  193  37  64 3 057 
21 27 Slovakia  3 2 884  -  32  37  51  8  6 3 021 
22 28 Italy  - 2 479  -  26  78  118  5  220 2 926 
23 30 Croatia  397 2 121  -  9  51  30  4 << 2 612 
24 31 Poland  221 2 055  - <<  171  1  20  23 2 491 
25 34 Andorra  - 2 203  -  -  74  71  13  - 2 361 
26 35 Portugal  89 1 454  -  6  601  -  11  5 2 166 
27 37 Serbia << 1 285  -  21  21 <<  2  494 1 823 
28 42 Lithuania <<  999  -  -  75 <<  19 << 1 093 
29 44 Montenegro  -  919  -  -  3  -  2  3  927 
30 45 Latvia  2  734  -  -  57  7  6  14  820 
31 46 Estonia <<  555  -  -  112  113  24  1  805 
32 47 Cyprus  -  474  -  -  72  81  39  -  666 
33 48 Bosnia and 
Herzegovina 
 1  460  -  -  17  - <<  140  618 
34 53 Bulgaria  -  95  -  -  197  31  8  81  412 
35 56 Malta <<  67  - <<  239  -  53  2  361 
36 69 Romania  -  93  -  1  34  40  5  -  173 
37 74 Belarus  -  118  -  -  14  -  -  24  156 
38 81 Russian 
Federation 
<<  75  -  -  12  -  -  20  107 
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39 98 Albania  -  28  -  -  20  -  3  18  69 
40 101 Republic of 
Moldova 
 -  30  -  -  27  -  -  9  66 
41 122 Ukraine  13  11  -  -  6  -  -  2  32 
42 127 The former 
Yugoslav 
Republic of 
Macedonia 
 -  25  -  -  1  -  -  -  26 
Regional average: Europe  32 3 707  6  104  398  288  11  689 5 236 
 
Note: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
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D. Average consumption of narcotic drugs in East and South-East Asia, South Asia and West 
Asia, 2007-2009 
 (Defined daily doses for statistical purposes per million inhabitants per day) 
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East and South-East Asia 
 1 2 39 Republic of 
Korea 
 15 1 079 16  26  50  128  15  13 1 342
 2 3 43 Japan  25  805  -  -  76  98  3  16 1 023
 3 6 62 Hong Kong, 
China 
<<  89  2 <<  86 <<  20  11  208
 4 7 63 Singapore <<  127 <<  -  31  20  19 <<  197
 5 13 73 Macao, China  -  100  -  -  42 <<  16 <<  158
 6 15 80 Malaysia  -  60  -  -  33  5  18 <<  116
 7 16 86 Brunei 
Darussalam 
 -  34  -  -  33  -  20  2  89
 8 19 99 China  2  37 << <<  17  2  10 <<  68
 9 20 100 Thailand <<  36  -  -  23  -  8  -  67
 10 23 110 Mongolia  2  6  -  -  47  -  -  1  56
 11 26 125 Democratic 
People’s 
Republic of 
Korea 
 7  -  -  -  23  -  -  -  30
 12 27 126 Viet Nam  -  17  -  -  8  -  4  -  29
 13 35 145 Philippines  -  4  - <<  4  2  1  -  11
 14 36 148 Indonesia  -  6  -  -  1  -  2  -  9
 15 41 157 Cambodia  1  3  -  -  2  - <<  -  6
 16 43 159 Lao People’s 
Democratic 
Republica 
 -  1 <<  - <<  -  2  -  3
 17 47 179 Myanmar << <<  -  - <<  - << << <<
Regional average: East and  
South-East Asia 
 3  102 <<  1  19  4  11  8  146
South Asia 
 1 28 127 Sri Lanka  -  3  -  -  16  -  7  -  26
 2 29 130 Bhutanb  7  1  -  -  3  -  10  -  21
 3 30 134 India  -  4  1  -  8 << <<  4  17
 4 34 144 Maldivesa  -  3  -  -  4  -  5  -  12
 5 36 148 Nepal  -  1  -  -  6  -  2  -  9
 6 40 153 Bangladesha  -  1  -  -  1  -  5  -  7
Regional average: South Asia <<  3  1  -  7 <<  1  4  17
West Asia 
 1 1 23 Israel  86 2 719  -  2  140  500  26  9 3 482
 2 4 50 Turkey  -  513  -  -  23  -  15  44  595
 3 5 60 Bahrain  2  131  -  -  47  -  51  -  231
 4 8 64 Saudi Arabiaa  22  132  -  1  16  2  22 <<  195
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 5 9 65 Kuwait  6  126  - <<  13  5  41  -  191
 6 10 66 Jordan  -  111  - <<  43  -  32  -  186
 7 11 67 Lebanon  -  125  -  -  35  -  24  1  185
 
8 12 68 United Arab 
Emirates 
<<  143  -  4  14  3  11  4  179
 9 14 75 Qatar  1  100  -  -  27  1  22  2  153
 10 17 94 Georgia <<  33  -  -  39  -  -  2  74
 
11 18 96 Syrian Arab 
Republic 
 -  23  -  -  3  35  11  -  72
 12 21 102 Kazakhstan <<  40  -  -  4  -  -  20  64
 13 22 103 Oman  1  33  -  -  19  -  10 <<  63
 
14 24 115 Iran (Islamic 
Republic of ) 
 -  28  -  -  -  -  18  -  46
 15 25 117 Armenia  -  14  -  -  26  -  -  2  42
 16 31 136 Azerbaijan  -  11  -  -  2  -  -  2  15
    Turkmenistan <<  3  -  -  6  -  -  6  15
 18 33 140 Kyrgyzstan <<  9  -  -  2  -  -  3  14
 19 36 148 Yemen  -  7  - <<  1  -  1  -  9
 20 39 151 Uzbekistan <<  3  -  -  3  -  -  2  8
 21 41 157 Iraqb  -  1  -  -  1  -  4  -  6
 22 43 159 Pakistan  -  2  -  -  1  - <<  -  3
    Tajikistan <<  2  -  - <<  -  -  1  3
 24 46 174 Afghanistanb  - <<  -  -  1  - <<  -  1
Regional average: West Asia  2  123  - <<  8  8  7  7  155
Average: Asia  2  72  1 <<  14  7  5  4  105
 
Notes: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
As at 1 November 2010, in East and South-East Asia, the following country had not submitted any statistical forms for the 
three consecutive years in question: Timor-Leste. 
a Calculation is based on data covering two years only. 
b Calculation is based on data covering one year only. 
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E. Average consumption of narcotic drugs in Africa, 2007-2009 
 (Defined daily doses for statistical purposes per million inhabitants per day) 
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1 49 South Africa  63  274  -  -  125 <<  32  106 600 
2 70 Saint Helena  77  26  -  -  38  -  26  - 167 
3 72 Algeria  -  26  -  -  3  - <<  133 162 
4 77 Tunisia  -  61  -  -  59  -  3  - 123 
5 78 Seychelles  4  16  -  -  85  -  15  - 120 
6 89 Libyan Arab 
Jamahiriyaa 
<<  62  -  -  1  -  23  - 86 
7 93 Mauritiusa  -  15  -  -  24  -  36  - 75 
8 95 Ascension 
Islanda 
 -  21  -  -  14  -  38  - 73 
9 107 Tristan da 
Cunhaa 
 -  -  -  -  55  -  3  - 58 
10 109 Namibia <<  22  -  -  27  -  7  1 57 
11 112 Cape Verde  -  37  -  -  9  -  3  - 49 
  Egypt  -  41 << <<  4 <<  4  - 49 
13 120 Morocco  -  26  -  -  7  -  -  - 33 
14 130 Botswana  -  1  -  -  15  -  5 <<  21 
15 132 Ugandaa  5  -  -  -  13  -  1  -  19 
16 133 Zimbabwea  -  1  -  -  6  -  8  3  18 
17 135 Kenya  -  1  -  -  6  -  6  3  16 
18 136 Ghana  - <<  -  -  1  -  14  -  15 
19 140 Zambia  - <<  -  -  4  -  10  -  14 
Madagascar  -  1  -  - <<  -  -  12  13 
20 142 
Malawi << <<  -  -  5  -  8  -  13 
22 146 Gabonb  -  10  -  - <<  - <<  -  10 
23 151 Lesothoa  -  1  -  - <<  -  7  -  8 
Democratic 
Republic of the 
Congo 
 4 <<  -  -  2  - <<  -  7 
Mozambique  -  2  -  -  4  -  1  -  7 24 153 
Sao Tome and 
Principe 
 -  7  -  - <<  -  -  -  7 
Mauritaniaa  -  3  -  - <<  -  -  -  3 
27 159 
Senegala  -  1  -  -  2  -  -  -  3 
Angolaa  -  1  -  - <<  - <<  -  2 
Benin  -  1  -  - <<  -  1  -  2 
Côte d’Ivoire  -  2  -  - <<  -  -  -  2 
Eritrea  1  -  -  - <<  -  1  -  2 
Ethiopiaa << <<  -  -  1  -  1  -  2 
Niger <<  2  -  - <<  - <<  -  2 
Sierra Leoneb  2 <<  -  - <<  - <<  -  2 
29 165 
Togo  -  1  -  - <<  -  1  -  2 
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Burkina Faso  -  1  -  - <<  - <<  -  1 
Burundia << <<  -  - <<  -  1  -  1 
Comorosb  -  -  -  - <<  -  1  -  1 
37 174 
Sudan  - <<  -  - <<  -  1  -  1 
Cameroona  - <<  -  - <<  - << << << 
Chadb  - <<  -  - <<  - <<  - << 
Malia  - <<  -  - <<  -  -  - << 
Nigeria  - <<  -  - <<  - <<  - << 
Rwanda  - <<  -  - <<  - <<  - << 
41 179 
United Republic 
of Tanzania 
 -  -  -  - <<  -  - << << 
Regional average: Africa  4  22 << <<  10 <<  3  11  50 
 
Notes: The symbol “<<” indicates an amount less than 1 defined daily dose for statistical purposes per million inhabitants  
per day. 
As at 1 November 2010, the following 10 countries either had not submitted any statistical forms or had not provided any 
consumption data for the three consecutive years in question: Central African Republic, Congo, Djibouti, Equatorial Guinea, 
Gambia, Guinea, Guinea-Bissau, Liberia, Somalia and Swaziland. 
a Calculation is based on data covering two years only. 
b Calculation is based on data covering one year only. 
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Annex II  
 
Joint letter from the President of the International Narcotics 
Control Board and the Chair of the United Nations  
Development Group 
 
 
 
24 August 2001 
Dear Colleagues, 
 As Resident Coordinator of the UN system at the country level, you are called upon, from time to 
time, to support the work and raise the concerns of UN bodies and organizations. We are writing to you to 
seek your support and assistance with regard to some of the issues and concerns important to the 
International Narcotics Control Board (INCB). 
 The INCB is the independent and quasi-judicial organ that monitors the implementation of the 
international drug control treaties. The Board is a treaty body established by the Single Convention on 
Narcotic Drugs of 1961, and its thirteen members are elected by ECOSOC to serve in their personal 
capacities, and not as representatives of their respective governments. The members of the Board come from 
different fields of expertise in dealing with the drug problem, and currently include senior police/law 
enforcement officials, former diplomats, veteran medical practitioners, noted researchers and the like. The 
1961 Convention requires the UN Secretary-General to provide the Board with a secretariat, and the 
Secretary of the Board and his staff are therefore administratively part of the United Nations International 
Drug Control Programme (UNDCP) based in Vienna, Austria and report to the Board on all substantive 
issues. The Board’s mandate under the Conventions is to limit to medical and scientific purposes the 
manufacture of, trade in and use of drugs. The Board is accordingly endowed with regulatory and quasi-
judicial powers concerning the manufacture of, and trade in, medicaments containing internationally 
scheduled substances. The Board and its staff also monitor the international trade in chemicals frequently 
used in the illicit manufacture of drugs. 
 The Board’s annual report for 1999 highlighted the under-consumption and the lack of medicaments 
available for the treatment of severe pain in many developing countries. Countries with a high incidence of 
cancer and AIDS, for example, are directly affected as essential medicines for the treatment of severe pain 
associated with such conditions are often not available. We therefore urge you to be aware of these issues 
when you establish your future priorities in programmes for the development of the health sector. We also 
urge you to raise this issue when you discuss health and development with government, the donor 
community and non-governmental organizations in your country of operation. 
 Further, the INCB undertakes periodic missions to our programme countries. The purpose of the 
missions, which generally comprise one or two Board members and a member of the Vienna-based 
secretariat, varies from country to country, and could range from encouraging accession to one or more of the 
international drug control treaties to close examination of the implementation of the treaties and fact finding. 
We urge each one of you to provide your full support to these missions, and to meet with the missions to 
discuss drug issues in your country of operation. 
 Finally, the Board launches an annual report, usually in late February, assessing the world drug 
situation in relation to the international drug control conventions and reporting on the activities of the 
preceding year. Your support for this event will be very much appreciated. 
 We look forward to your cooperation and participation, as the Resident Coordinator of the UN system 
at the country level, in these areas where our mutual expertise in development work and the international 
drug conventions can make a difference. 
    
  Mark Malloch Brown      Hamid Ghodse 
   Chair            President 
 United Nations Development Group     International Narcotics Control Board 
UNITED NATIONS NATIONS UNIES 
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Annex III 
 
Follow-up joint letter from the President of the International 
Narcotics Control Board and the Chair of the United Nations 
Development Group 
 
 
24 February 2005 
 
Dear Resident Coordinators, 
 As Resident Coordinators of the UN system at the country level, you are called upon to support the 
work as well as raise the concerns of UN bodies and organizations. As was the case in 2001, we are again 
pleased to introduce the International Narcotics Control Board to you and to renew our call for your support 
and assistance with regard to the issues and concerns the Board addresses. 
 The INCB is a treaty body established by the Single Convention on Narcotic Drugs of 1961 that 
monitors the implementation of the international drug control treaties. It is an independent and quasi-judicial 
body composed of 13 members elected by ECOSOC to serve in their personal capacities, and not as 
representatives of their respective governments. The members of the Board are renowned experts of the 
different control fields. The present Board comprises senior law enforcement officials, former diplomats, 
veteran medical practitioners and pharmacists, demand reduction specialists, and noted academics and 
researchers. 
 The Board is assisted in its work by a secretariat provided by the UN Secretary-General, and headed 
by a Secretary. The Secretariat and the Secretary of the Board and his colleagues are administratively part of 
the United Nations Office on Drugs and Crime (UNODC) based in Vienna. However, the Secretary reports 
to the Board on all substantive issues. 
 The Board’s mandate under the Convention is to limit to medical and scientific purposes the 
manufacture of, trade in and use of drugs. The Board is accordingly endowed with regulatory and quasi-
judicial powers concerning the manufacture of, and trade in, medicaments containing internationally 
scheduled substances. Since the coming into force of the 1988 Convention, the Board also monitors the 
international trade in chemicals frequently used in the illicit manufacture of drugs. 
 The specific areas of cooperation we would request of you, as Resident Coordinators, include: 
 Field missions: To maintain dialogue at country level, the Board undertakes annually about 20 
missions to different regions of the world. The purpose of the missions, which generally comprise one or two 
Board members accompanied by a staff of its Vienna-based secretariat, varies from country to country, but 
usually ranges from encouraging member States to accede to the international drug control treaties to close 
examination of the implementation of the treaties by governments. 
 The missions are generally prepared and organized from the logistical point of view in cooperation 
with governments and UNODC. However, in many places, your assistance is required either for arranging 
the mission or providing substantive briefing to INCB mission members on the drug situation in your country 
of operation. 
 Launch of INCB annual reports: The Board publishes an annual report on its work, which is 
launched usually in February. While this is done in cooperation with UNIS, you may be called upon to assist 
either at the request of the INCB or a government. 
 Dissemination of the findings of the Board: The findings in the Board reports are disseminated 
worldwide to the general public through national and international channels. You may be called upon by 
INCB to assist in this process.  
UNITED NATIONS NATIONS UNIES
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 Action-oriented programmes: The issues addressed by the Board serve as the basis for policy and 
action-oriented programmes in drug control and related matters. Examples of issues dealt with by the Board 
recently include the access and availability of drugs for medical use, especially in developing countries; 
illicit drugs and economic development and the complex relationship between drug abuse, crime and 
violence at the community level. As you can see, these issues are of direct relevance to UNDP’s mandate. As 
Resident Representatives of UNDP and UN Resident Coordinators, we request you to consider their 
inclusion in your future priorities in development programmes, and to raise them when you discuss with 
government, the donor community and non-governmental organizations in your country of operation. 
 We look forward to your cooperation and participation, as the Resident Coordinator of the UN system 
at the country level, in these areas where our mutual expertise in development work and international drug 
control can make a difference. 
    
  Mark Malloch Brown      Hamid Ghodse 
   Chair            President 
 United Nations Development Group     International Narcotics Control Board 
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Annex IV  
   
Letter from the President of the International Narcotics Control 
Board to all countries 
   
 
 
 
 
 
 
 
 
 
Excellency, 
 On behalf of the United Nations International Narcotics Control Board (INCB), I have the honour to 
refer to the responsibilities of the Board under the international drug control treaties, which are to promote 
Government compliance with those treaties and to monitor the functioning of the international control 
system. 
 With a history of nearly a century, the international drug control conventions are among the oldest 
international conventions ratified by most countries. National legislations are guided by these international 
obligations. The purpose of the conventions was to secure a balance between the appropriate use of narcotic 
drugs and psychotropic substances and their undesirable effects such as abuse and dependence. The 
cornerstone of the conventions is therefore to limit the use of these drugs and substances to medical and 
scientific purposes. Over recent years, the Board has brought to the attention of the governments that, in 
addition to international control of production/manufacture and international trade, there is a need for other 
aspects of prevention, particularly demand reduction, to be promoted and advanced, if substance abuse and 
dependence are going to be prevented. 
 Health care professionals can play an important role in these efforts by ensuring that the balance 
between benefit and risk is kept in mind and that the use of narcotic drugs and psychotropic substances is 
appropriate and in line with the pertinent recommendations of the World Health Organization (WHO) on the 
rational use of drugs. However, there are problems of access to these very effective drugs for needy patients 
due to a variety of reasons which were discussed in the Board’s Report for 1999. Overuse of drugs in some 
countries creates other problems and this aspect was covered comprehensively in the Board’s Report for 
2000. For example, just six countries account for the use of 80% of licitly produced narcotic analgesics while 
80% of the world’s population have very little or no access to these drugs. 
 Universities are well placed to understand the different factors that affect health in relation to human 
development and to monitor ways in which such development can be used to enhance the quality of life. The 
Board therefore believes that the education and training of professionals involved in the caring professions 
and, as appropriate, of those in law and regulatory disciplines as well as social and behavioural sciences, is of 
the utmost importance. Universities clearly have a prominent role in leadership in this area, not only in 
research and advocacy, but also by ensuring that the relevant topics are included in undergraduate and 
postgraduate curricula. 
  
UNITED NATIONS 
INTERNATIONAL  
NARCOTICS 
CONTROL BOARD 
NATIONS UNIES ORGANE 
INTERNATIONAL DE 
CONTRÔLE DES 
STUPÉFIANTS 
 INCB    OICS 
Vienna International Centre, P.O. Box 500, A-1400 Vienna, Austria 
Telephone: +43-1-26060, Telefax: +43-1-26060-5867/5868, Telex: 135612 uno a 
E-Mail: secretariat@incb.org   Internet Address: http://www.incb.org/ 
Reference: INCB 114 (3) & 121 & 141 
Decision: 84/53 
24 April 2006 
CU 2006/74 
REPORT ON THE AVAILABILITY OF INTERNATIONALLY CONTROLLED DRUGS 
 
74 
 
 The Board has requested me to bring these views to the attention of your Government. In particular, 
the Board wishes to encourage your Government to take measures to ensure the inclusion of the subject of 
the rational use of drugs for medical purposes and the risks associated with substance abuse and addictions to 
drugs in the curricula of the appropriate faculties in the universities, taking into account the need for coherent 
programmes in the various fields of study. Concerted action in this field could also cover misuse and abuse 
of alcohol and tobacco, although the Board has no mandate in these areas. The Board would respectfully 
request you to bring this to the attention of ministers of higher education, chancellors of the universities and 
other appropriate ministries, for their consideration. 
 The Board and its secretariat are happy to provide your Government and universities, with copies of 
INCB annual reports and publications to facilitate the development of such curricula. 
 I am attaching a brochure presenting the Board and its functions for your information. 
 Accept, Excellency, the assurance of my highest consideration.  
         
         Hamid Ghodse 
              President 
             International Narcotics Control Board 
  
About the International Narcotics Control Board 
 
 
 The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, 
established by treaty, for monitoring the implementation of the international drug control treaties. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations. 
 
Composition 
 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their 
personal capacity, not as Government representatives. Three members with medical, pharmacological or 
pharmaceutical experience are elected from a list of persons nominated by the World Health Organization (WHO) and 
10 members are elected from a list of persons nominated by Governments. Members of the Board are persons who, by 
their competence, impartiality and disinterestedness, command general confidence. The Council, in consultation with 
INCB, makes all arrangements necessary to ensure the full technical independence of the Board in carrying out its 
functions. INCB has a secretariat that assists it in the exercise of its treaty-related functions. The INCB secretariat is an 
administrative entity of the United Nations Office on Drugs and Crime, but it reports solely to the Board on matters of 
substance. INCB closely collaborates with the Office in the framework of arrangements approved by the Council in its 
resolution 1991/48. INCB also cooperates with other international bodies concerned with drug control, including not 
only the Council and its Commission on Narcotic Drugs, but also the relevant specialized agencies of the United 
Nations, particularly WHO. It also cooperates with bodies outside the United Nations system, especially the 
International Criminal Police Organization (INTERPOL) and the World Customs Organization. 
 
Functions 
 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following: 
 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control over 
chemicals used in the illicit manufacture of drugs and assists them in preventing the diversion of those chemicals into 
the illicit traffic; 
 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contributes to correcting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of drugs, in order to determine whether they should be placed 
under international control. 
 
 In the discharge of its responsibilities, INCB: 
 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs through a statistical returns system, with a view to assisting 
Governments in achieving, inter alia, a balance between supply and demand; 
 
 (b)  Monitors and promotes measures taken by Governments to prevent the diversion of substances frequently 
used in the illicit manufacture of narcotic drugs and psychotropic substances and assesses such substances to 
determine whether there is a need for changes in the scope of control of Tables I and II of the 1988 Convention; 
 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other 
competent international organizations, with a view to ensuring that the provisions of the international drug control 
treaties are adequately carried out by Governments, and recommends remedial measures; 
 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations 
under the international drug control treaties and, to that end, recommends, where appropriate, technical or financial 
assistance to be provided. 
 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose 
appropriate remedial measures to Governments that are not fully applying the provisions of the treaties or are 
encountering difficulties in applying them and, where necessary, to assist Governments in overcoming such difficulties. 
If, however, INCB notes that the measures necessary to remedy a serious situation have not been taken, it may call the 
matter to the attention of the parties concerned, the Commission on Narcotic Drugs and the Economic and Social 
  
Council. As a last resort, the treaties empower INCB to recommend to parties that they stop importing drugs from a 
defaulting country, exporting drugs to it or both. In all cases, INCB acts in close cooperation with Governments. 
 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it 
proposes and participates in regional training seminars and programmes for drug control administrators. 
 
Reports 
 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation worldwide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at both the national and international levels. The annual report is 
based on information provided by Governments to INCB, United Nations entities and other organizations. It also uses 
information provided through other international organizations, such as INTERPOL and the World Customs 
Organization, as well as regional organizations. 
 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit 
movement of narcotic drugs and psychotropic substances required for medical and scientific purposes, together with 
an analysis of those data by INCB. Those data are required for the proper functioning of the system of control over the 
licit movement of narcotic drugs and psychotropic substances, including preventing their diversion to illicit channels. 
Moreover, under the provisions of article 12 of the 1988 Convention, INCB reports annually to the Commission on 
Narcotic Drugs on the implementation of that article. That report, which gives an account of the results of the 
monitoring of precursors and of the chemicals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, is also published as a supplement to the annual report. 
 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which 
INCB presents its conclusions and recommendations in order to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The following topics were covered in past annual reports: 
 
 1992: Legalization of the non-medical use of drugs 
 1993: The importance of demand reduction 
 1994: Evaluation of the effectiveness of the international drug control treaties 
 1995: Giving more priority to combating money-laundering 
 1996: Drug abuse and the criminal justice system 
 1997: Preventing drug abuse in an environment of illicit drug promotion 
 1998: International control of drugs: past, present and future 
 1999: Freedom from pain and suffering 
 2000: Overconsumption of internationally controlled drugs 
 2001: Globalization and new technologies: challenges to drug law enforcement in the twenty-first century 
 2002: Illicit drugs and economic development 
 2003: Drugs, crime and violence: the microlevel impact 
 2004: Integration of supply and demand reduction strategies: moving beyond a balanced approach 
 2005: Alternative development and legitimate livelihoods 
 2006: Internationally controlled drugs and the unregulated market 
 2007: The principle of proportionality and drug-related offences 
 2008: The international drug control conventions: history, achievements and challenges 
 2009: Primary prevention of drug abuse 
 
 Chapter I of the report of the International Narcotics Control Board for 2010 is entitled “Drugs and corruption”. 
 
 Chapter II presents an analysis of the operation of the international drug control system based primarily on 
information that Governments are required to submit directly to INCB in accordance with the international drug 
control treaties. Its focus is on the worldwide control of all licit activities related to narcotic drugs and psychotropic 
substances, as well as chemicals used in the illicit manufacture of such drugs. 
 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by 
Governments to implement the international drug control treaties by addressing those problems. 
 
 Chapter IV presents the main recommendations addressed by INCB to Governments, the United Nations Office 
on Drugs and Crime, WHO and other relevant international and regional organizations. 
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